


Journal Pre-proof

Dual-acting agents for improving cognition and real-world function in Alzheimer's disease: Focus on 5-HT6 and D3 receptors as hubs

Mark J. Millan, Anne Dekeyne, Alain Gobert, Mauricette Brocco, Clotilde Mannoury la Cour, Jean-Claude Ortuno, David Watson, Kevin C.F. Fone



PII: S0028-3908(20)30167-2

DOI: <https://doi.org/10.1016/j.neuropharm.2020.108099>

Reference: NP 108099

To appear in: *Neuropharmacology*

Received Date: 11 February 2020

Revised Date: 2 April 2020

Accepted Date: 3 April 2020

Please cite this article as: Millan, M.J., Dekeyne, A., Gobert, A., Brocco, M., Mannoury la Cour, C., Ortuno, J.-C., Watson, D., Fone, K.C.F., DUAL-ACTING AGENTS FOR IMPROVING COGNITION AND REAL-WORLD FUNCTION IN ALZHEIMER'S DISEASE: FOCUS ON 5-HT6 AND D3 RECEPTORS AS HUBS, *Neuropharmacology*, <https://doi.org/10.1016/j.neuropharm.2020.108099>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2020 Published by Elsevier Ltd.

DUAL-ACTING AGENTS FOR IMPROVING COGNITION AND REAL-WORLD FUNCTION IN ALZHEIMER'S DISEASE: FOCUS ON 5-HT6 AND D3 RECEPTORS AS HUBS

Mark J. Millan*, Anne Dekeyne*, Alain Gobert*, Mauricette Brocco, Clotilde Mannoury la Cour*, Jean-Claude Ortuno**, David Watson*** and Kevin C.F. Fone***

*Centre for Therapeutic Innovation in Neuropsychiatry, Institut de recherche Servier,
78290 Croissy sur Seine, France,

**Centre for Excellence in Chemistry, Institut de recherche Servier,
78290 Croissy sur Seine, France,

***School of Life Sciences, Queen's Medical Centre, The University of Nottingham, NG7 2UH,
England

Corresponding author:

Mark J. Millan mark.millan@servier.com

Abstract

To date, there are no interventions that impede the inexorable progression of Alzheimer's disease (AD), and currently-available drugs cholinesterase (AChE) inhibitors and the N-Methyl-D-Aspartate receptor antagonist, memantine, offer only modest symptomatic benefit. Moreover, a range of mechanistically-diverse agents (glutamatergic, histaminergic, monoaminergic, cholinergic) have disappointed in clinical trials, alone and/or in association with AChE inhibitors. This includes serotonin (5-HT) receptor-6 antagonists, despite compelling preclinical observations in rodents and primates suggesting a positive influence on cognition. The emphasis has so far been on *high* selectivity. However, for a multi-factorial disorder like idiopathic AD, 5-HT6 antagonists possessing additional pharmacological actions might be more effective, by analogy to "multi-target" antipsychotics. Based on this notion, drug discovery programmes have coupled 5-HT6 blockade to 5-HT4 agonism and inhibition of AChE. Further, combined 5-HT6/dopamine D3 receptor (D3) antagonists are of especial interest since D3 blockade mirrors 5-HT6 antagonism in exerting broad-based pro-cognitive properties in animals. Moreover, 5-HT6 and dopamine D3 antagonists promote neurocognition and social cognition *via* both distinctive *and* convergent actions expressed mainly in frontal cortex, including suppression of mTOR over-activation and reinforcement of cholinergic and glutamatergic transmission. In addition, 5-HT6 blockade affords potential anti-anxiety, anti-depressive and anti-epileptic properties, and antagonising 5-HT6 receptors may be associated with neuroprotective ("disease-modifying") properties. Finally D3 antagonism may counter psychotic episodes and D3 receptors themselves offer a promising hub for multi-target agents. The present article reviews the status of "R and D" into multi-target 5-HT6 and D3 ligands for improved treatment of AD and other neurodegenerative disorders of aging.

Key Words

Social cognition, novel object recognition, prefrontal cortex, hippocampus, mTOR, cognition, learning, memory, multi-target, GABA, psychosis, amyloid, tau, dementia.

Introduction: Alzheimer's disease and its current treatment

AD, which accounts for some 60 to 70 % of cases of dementia, is characterised by a bewildering suite of risk factors, a panoply of cognitive and psychiatric symptoms, and a diversity of mutually-reinforcing pathophysiological changes, with heterogeneity amongst patients translating into differential responsiveness to treatments (**Figure 1**) (Deardorff and Grossberg, 2019; Sala Frigerio and De Strooper, 2017; Joe and Ringman, 2019; Scheltens et al, 2016). Clinical diagnosis occurs only decades after the emergence of cellular pathology, but improvements in the imaging of β -amyloid and Tau, in the detection of these neurotoxic proteins in biofluids, and in the application of biomarkers like circulating miRNAs, polygenic scores, environmental risk factors and electroencephalography offer prospects for pinpointing vulnerable subjects and hence more precocious intervention (Chasioti et al, 2019; Cummings, 2019; Eid et al, 2019; Gaubert et al, 2019; Leuzy et al; 2019; Millan, 2017; Molinuevo et al, 2018). Despite enormous efforts to develop drugs that block the accumulation and aggregation of β -amyloid, clinical trials have not yet led to authorisation, although there still remain some irons in the fire (Aducanumab data have been resuscitated and this antibody against β -amyloid, which markedly reduces its levels in the brain and provides some cognitive benefit, will be proposed to the FDA in Spring 2020) (Howard and Liu, 2019; Sevigny et al, 2016). Further, efforts are continuing to impede the onset and progression of AD by interfering with the aberrant processing, folding and spread of tau, countering neuroinflammation and restoring cerebral energetics (Boland et al, 2018; Cunnane et al, in press; Paouri and Georgopoulos, 2019; Ryu et al, 2019; Scheltens et al, 2016; Veitch et al, 2019). In parallel, the adoption of life-style changes embracing Mediterranean and related diets, regular exercise and improved sleep may be related to the *decreasing* incidence of AD, a contention supported by the relative success of the "FINGER" trial, with improved control of cardiovascular risks factors also helping curtail the development of AD (Ngandu et al, 2015; Park et al, 2019; Saito et al, 2019).

It is crucial to better understand the pathological mechanisms driving AD, other forms of dementia and related neurodegenerative diseases of aging, and to advance disease-modifying medication for course-alteration (Sala Frigerio and De Strooper, 2017; Scheltens et al, 2016; Veitch et al, 2019). Nonetheless, notwithstanding a litany of failures in the past, it is important not to forego efforts to improve *symptoms* in patients at various stages of the disorder from Mild Cognitive Impairment (MCI) to late stage AD *via* mechanisms that do *not* necessarily attack the pathological foundations of the disorder (Alam et al, 2017; Birks and Harvey, 2018; Dou et al, 2018; Joe and Ringman, 2019; Kandiah et al, 2017; McShane et al, 2019; Parsons et al, 1999; Scheltens et al, 2016). Indeed, it would seem ethically questionable to abandon those tens of millions of subjects already suffering from AD yet unlikely to benefit from future progress in disease-modifying therapy. This is particularly true since the few agents currently authorised to treat AD target only *two* mechanisms of action: inhibition of AChE (donepezil, galantamine and rivastigmine) and low affinity antagonism of N-Methyl-D-Aspartate (NMDA) receptors (memantine). Moreover, these medications manifest only modest efficacy for restoration of cognitive performance and global function, with little improvement in neuropsychiatric symptoms (Alam et al, 2017; Birks and Harvey, 2018; Francis

et al, 2012; Joe and Ringman, 2019; McShane et al, 2019; Parsons et al, 1999). The failure to generate innovative agents for treating the symptoms of AD is starkly displayed in **Figure 2** in comparison to the steady stream of mechanistically-diverse drugs (and other classes of intervention) for treating major depression, although this is not to claim that the management of depression is anywhere near ideal, in particular as regards the problems of resistance and partial responsiveness (Millan, 2006; Millan et al, 2015 ; Wilkinson and Sanacora, 2018).

As regards the improved control of symptoms in AD, a strategy beyond the purely neurocognitive would be advisable, including social cognition which is also strongly affected in AD, neuropsychiatric symptoms like aggression, confusion, anxiety and depression, disrupted sleep patterns, anomalous circadian rhythms, motor anomalies and poor nutrition and energy balance (Christidi et al, 2018; Deardorff and Grossberg 2019; Henry et al; 2016; McArdle et al, 2017; McClam et al, 2015; Peralta and Cuesta; 2017; Porceli et al, 2019; Ryu et al, 2019; Wise et al, 2019). The influence of interventions should best be monitored using improved readouts as compared to those conventionally employed to date. In this respect, both for AD and for its earlier, preclinical manifestations, one might hope for the emergence of revised rating scales, a mixture of self- and carer-effected quantification of treatment impact, novel readouts and the insightful use of digital real-world monitoring and other nascent technologies (Gold et al, 2018; Kueper et al, 2018; Piau et al, 2019; Porceli et al, 2018; Veitch et al, 2019).

Finding broadly-effective, course-altering and symptomatic treatments for AD will not be an easy task and, in addition to their exploitation upon a favourable life-style and energetic background, interventions with multiple and *complementary* mechanisms of action may have the greatest chance of success in view of the complexity and diversity of the disorder. Indeed, an excessive penchant for high selectivity may have compromised the effectiveness of many potentially useful targets for altering the course of AD – not to mention other complex CNS disorders. One single mechanism of action (MOA) may not be sufficient to reach the threshold for clinically-demonstrable efficacy, explaining why certain agents have not proven successful in the clinic despite encouraging preclinical observations (see below) (de Freitas Silva et al, 2019; Millan, 2006; Sahoo et al, 2018; Zhang et al, 2019).

Available drugs for treating cognitive deficits in AD: limited efficacy and therapeutic range

As shown in **Figure 2**, only four agents are currently authorised for treating the cognitive impairment of AD. Three of these are inhibitors of AChE (donepezil, galantamine and rivastigmine) (Alam et al, 2017; Joe and Ringman, 2019; Kandiah et al, 2017; Parsons et al, 1999; Tricco et al, 2018). Though AChE inhibitors should recruit several classes of post-synaptic nicotinic and muscarinic receptor, their respective contributions to relief of cognitive disruption in AD remains unknown (Verma et al, 2018). Acetylcholine levels are also regulated by butyrylcholinesterase (mainly localised in glia and white matter), so the additional actions of rivastigmine at this enzyme may reinforce its ability to protect ACh from degradation as well as, speculatively, impeding disease progression, though such advantages have yet to be proven in the clinic (Birks and Harvey, 2018; Darvesh, 2016; Joe and Ringman, 2019; Kandiah et al, 2017).

In addition, galantamine purportedly possesses antagonist properties at nicotinic receptors, but the clinical relevance of this potential action has been strongly questioned (Kowal et al, 2018).

Memantine, authorised for the treatment of moderate to severe AD, is a fast on/off kinetic, voltage-dependent, non-competitive antagonist (“channel blocker”) of moderate affinity at NMDA receptors (Alam et al, 2017; Francis et al, 2012; McShane et al, 2018; Parsons et al, 2013; Parsons et al, 1999). Interestingly, memantine has a number of other low affinity interactions at various ion channels and other sites (Parsons et al, 1999), but it is unclear to what extent they contribute to its clinical influence on cognitive function. Finally, possibly reflecting convergent recruitment of “glutamatergic” and cholinergic mechanisms, memantine and AChE inhibitors are often administered in association, and a fixed combination of memantine and donepezil (“Namzaric”) has been introduced in the US (Francis et al, 2012; Kennedy et al, 2018; Matsunaga et al, 2014; Parsons et al, 2013; Schmidt et al, 2015)

Astonishingly, or shockingly perhaps, since 2000 and the introduction of memantine, no further agent has been authorized for treatment of the cognitive deficits of AD. This dearth of new treatments is a serious issue for patients and carers alike in view of the only modest clinical benefits of currently available agents : this penury also contrasts starkly with the abundance of novel therapies for countering major depression (*vide supra*) (Figure 2). Moreover, in distinction to psychosocial-cognitive-behavioural and stimulation therapies, despite some encouraging progress, no “alternative“ treatments are as yet formally available to improve cognitive dysfunction in AD (Arendash et al, 2019; Chang et al, 2018). Moreover, despite extensive efforts and considerable progress in understanding the neural underpinnings of AD, strategies for interrupting its relentless progress have not yet been identified.

The need to counter cognitive impairment and other neuropsychiatric symptoms of AD

The above observations underpin the importance of continuing to seek novel approaches for relieving the cognitive impairment and other symptoms of AD. Indeed, for patients already diagnosed with AD, it is unlikely that they will benefit from any imminent or future disease-modifying therapies that impede the onset or progression of AD (Joe and Ringman, 2019; Lanctot et al, 2017; Stahl, 2018). A key point here is the need to look beyond classic learning and memory deficits in attempting to restore other domains of impairment, in particular social cognition (Christidi et al, 2018; Porcelli et al, 2019). Furthermore, the motor and highly disruptive “neuropsychiatric” symptoms of AD have not been sufficiently explored for potential therapeutic improvement. They include impairments in sleep and circadian rhythms, anxiodepressive states that respond poorly to existing agents, aggressiveness and irritability (Deardorff and Grossberg 2019; Lanctot et al, 2017; McClam et al, 2018; Peralta and Cuesta; 2017; Wise et al, 2018). Another frequent complication of AD is psychosis, often associated with agitation: this is especially problematic since antipsychotic use is risky and discouraged in elderly patients with AD, although risperidone is currently the best-supported option (Creese et al, 2018; Deardorff and Grossberg, 2019; Lanctot et al, 2017).

Ideally, one would devise agents capable of improving multiple domains of dysfunction, although it is unclear whether they can be achieved with any single MOA.

Poor efficacy of highly selective agents for treating cognitive deficits in AD

Notwithstanding an impressive suite of preclinical observations and solid conceptual foundations, a broad array of highly-selective agents have failed to attain efficacy sufficient for authorisation for the improvement of cognitive performance in AD. These include agonists at specific subtypes of nicotinic and muscarinic receptor (Verma et al, 2018), positive allosteric modulators (PAMs) of α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors (Bernard et al, 2019), antagonists (or inverse agonists) at histamine H3 receptors (Kubo et al, 2015), 5-HT4 receptor agonists (Lalut et al, 2016) and inhibitors of Phosphodiesterase 4A (Prickaerts et al, 2017). (We will come to 5-HT6 antagonists below). Quite apart from a *putative* lack of target relevance, reasons underlying the lack of success are complex and lie beyond the compass of this review (Cummings, 2019; Drummond and Wisniewski, 2017; Khoury et al, 2018; Molinuevo et al, 2018; Mullane and Williams, 2019; Neuner et al, 2019; Sabbagh et al, 2019). We may nonetheless one evoke such general issues as:

- Inadequate experimental validation, notably a paucity of studies of the influence of agents in animal models for AD, whereby their ability to “normalize” disrupted cognitive performance is established, preferably under long-term administration and employing a variety of behavioural and neurochemical readouts. This is of greater relevance that shifts in “baseline” cognition or reversals of delay-and pharmacologically induced disruption of performance but, of course, such investigations are far more onerous, and not realistic for early screening.
- Following up the previous point, poor translation of drug target, with insufficient data linking results from animal tests of cognition, electrophysiology, neurochemistry and endocrine status etc to observations in patients with AD;
- Failure to prove appropriate target engagement in patients (in certain cases owing to a lack of radioligands allowing *in vivo* imaging in humans) at doses employed clinically;
Drawbacks of classic rating scales and procedures like the omnipresent and *de rigueur* yet far-from-perfect “ADAS-cog”;
- The loss of a robust signal for one specific cognitive domain in overall assessments of cognitive impact;
- Substantial inter-individual variability amongst poorly stratified populations of AD patient;
- Alterations in clinical procedures, drug dose and schedule, and outcome measure etc following a successful Phase II upon shifting to the determinant Phase III.

More specific concerns include rapid receptor desensitization for targets like nicotinic and AMPA receptors, and a low therapeutic window between doses required for a robust therapeutic effect compared to those triggering adverse effects, notably for AMPA modulators and Phosphodiesterase inhibitors (Coombs

et al, 2019; Joe and Ringman, 2019; Prickaerts et al, 2017; Verma et al, 2018). It is also possible that outcome in measures of cognitive performance is modified by (a concomitant influence of agents on) poorly-controlled factors like the energetic status of the brain, diurnal rhythms and sleep, and the gut microbiota (Cunnane et al, in press; Kowalski and Mulak, 2019; Ryu et al, 2019; Van Erum et al, 2019).

Nonetheless, a more prosaic answer as to why so many promising agents have failed to exert robust, broad-based and clinically significant improvement of cognitive deficits in large populations of patients may be their exceptional selectivity for one specific class of target. Paradoxically, then, it is precisely this high degree of specificity that represents the Achilles' heel. This notion is of quite general relevance to the control of complex disorders - AIDS being the most familiar example - and is particularly relevant to AD in view of its multi-faceted and progressive pathophysiology (de Freitas Silva et al, 2019; Millan, 2006; Sahoo et al, 2018; Zhang et al, 2019). Furthermore, this notion is just as relevant to efforts to develop agents that interfere with disease processes driving AD as to those designed to alleviate its symptoms. There is a good degree of irony here in view of the almost blind obsession with selectivity that has typified many (in particular, « High Throughput Screening and so-called Rational Drug Discovery ») programmes of compound selection and characterisation; even to the point of eliminating a-la-robot potentially useful, unexpected properties of novel compounds rather than reinforcing and intelligently valorizing them (Millan, 2008). Perhaps the most peculiar aspect of all this is the dubious conclusion that the target is “wrong” or “doesn't work” following disappointing clinical trials with ligands of very high selectivity, a bit like concluding that the wheels on a car without a steering wheel “don't work” because it won't go in the right direction (Abbott and Dolgin, 2016; Bespalov et al, 2016; Millan, 2006, 2008). Rather, it may be that target would be more effectively exploitable in association with a *complementary* MOA for reinforcing efficacy while expanding the therapeutic window (side-effects should not be additive for two mechanisms of actions sharing pro-cognitive properties) (Millan, 2006).

The concept of multi-target strategies for AD, a multi-factorial disorder

The above-evoked issues underpin the notion that the association of two agents possessing complementary MOAs, or a single agent possessing itself two or more MOAs, may be more effective than highly selective compounds in the management of AD and other complex disorders (Cummings et al, 2019; de Freitas Silva et al; 2018; Millan, 2006; Umar and Hoda, 2019; Van der Schyf et al, 2006; Zhang et al; 2019). Such agents have been dubbed selectively non-selective (maintaining sites providing efficacy while dialling out those triggering side-effects), multi-modal, multi-functional, multi-target directed and multi-target amongst other appellations but we will stick to the latter term herein in view of its simplicity. Moreover, “functional” might be misconstrued as alluding to the roles of specific *chemical* elements, “multi-modal“ implies association of medication with other types of therapy like cognitive-behavioural and “selectively non-selective“ is a bit confusing for the non-initiated.

Irrespective of the appellation, the basic idea is that acting *via* two or more complementary MOAs should reinforce and broaden therapeutic efficacy in AD against cognitive impairment and other types of

symptom. These MOAs might in theory be up and downstream, such as the coupling of G protein coupled receptor ligand with 1), a Phosphodiesterase inhibitor to boost alterations in AMP and/or cGMP or 2), a suppressor of mammalian target of rapamycin (mTOR) (implicated in cognitive processes, see below) (Bockaert and Marin, 2015; Millan et al, 2008; Prickaerts et al, 2017). Alternatively, one might imagine agents that converge onto common neural substrates thought to promote cognition: here, cholinergic pathways and glutamatergic neurotransmission come to mind. Another possibility would be to act *via* independent cellular and/or neurotransmitter systems distributed across various cerebral structures impacted in AD in order to broaden and deepen therapeutic efficacy. In this case, one might hope for additional therapeutic benefits over and above relief of cognitive impairment, a notion advocated and explored below.

As illustrated in **Figure 3**, the frontal cortex, a projection site for many ascending pathways controlling cognition and mood is a site where multi-target agents designed to counter cognitive impairment and neuropsychiatric symptoms in AD could well interact (Millan et al, 2016; Sahoo et al, 2018; Zhang et al, 2019).

Influence of 5-HT₆ receptors upon cognition: preclinical studies and clinical trials in AD patients

5-HT₆ receptors, which are located postsynaptic to serotonergic neurons, are almost exclusively expressed in the CNS, supporting the notion that they can be modulated, stimulated or blocked while minimizing adverse, target-related side-effects (Charnay and Leger, 2010; Fone, 2008; Helboe et al, 2015; Hornung, 2003). The highest expression of receptor protein and mRNA in rats and man occurs in areas like the striatum, hippocampus and frontal cortex supporting a potential influence on cognition and mood (Chaumont-Dubel et al, 2019; Helboe et al, 2015; Millan et al, 2008). In the hippocampus and frontal cortex, 5-HT₆ receptors appear to be largely located on neuronal dendrites, and, somewhat unusually for a G-protein coupled receptor, on primary neuronal cilia of glutamatergic and GABAergic neurones (Brailov et al, 2000; Fone, 2008; Helboe et al, 2015; Hu et al, 2017) as well as some cholinergic neurones. Cilial location is interesting since these are hubs for integration of cellular signaling, and they may be implicated in the pathogenesis of AD (Armato et al, 2013; Brodsky et al, 2017; Chaumont-Dubel et al, 2019; Hu et al, 2019; Lesiak et al, 2018). GABAergic interneurons are themselves inhibitory to glutamatergic and other pathways controlling cognition (Millan et al, 2012 Kann, 2016; Zott et al 2018).

One peculiarity of 5-HT₆ receptors is their constitutive activity: that is, “spontaneous”, ligand-independent signaling in the absence of agonists *via*, for example, G_s and adenylyl cyclase (Chaumont-Dubel et al, 2019; Duhr et al, 2014; Dupuis et al, 2008; Millan et al 2008). This is seen at both recombinant and native populations of 5-HT₆ receptor in neurons, and can be influenced by various protein partners, though it is not entirely clear under which conditions (if any) cerebral populations of 5-HT₆ receptor would be completely deprived of 5-HT (Chaumont-Dubel et al, 2019; Deraredj Nadim et al, 2017). Based on current evidence, it appears that agents acting either as neutral antagonists (no intrinsic actions themselves while blocking the actions of both agonists and inverse agonists) or as inverse agonists are active in tests of

pro-cognitive activity. However, the precise relationship between negative efficacy and improved cognition is unclear - especially for human 5-HT₆ receptors under pathological conditions. This should be borne in mind in the comments below where, mainly for clarity and by convention, we refer to 5-HT₆ receptor “antagonists”.

A wealth of preclinical data (Codony, 2011; De Jong and Mork, 2017; King et al, 2008; Ramirez, 2013), has shown that selective 5-HT₆ receptor antagonists improve cognition in rats, mice and primates in a large array of behavioural paradigms: spatial learning and memory, associative learning and memory, autoshaping, attentional set-shifting, novel object discrimination and social recognition (Eskenazi et al, 2015; Fone, 2008; Hu et al, 2017; Loiseau et al, 2008; Ramirez, 2013; Woods et al, 2012; Woolley et al, 2001). They are effective in both young and old animals, they reverse GABAergic-, cholinergic- and glutamatergic-induced cognitive impairment (Aparicio-Nava et al, 2019; King et al, 2004; Loiseau et al, 2008; Woods et al, 2012) and, in microdialysis studies, they enhance acetylcholine and glutamate release in the frontal cortex and hippocampus (Codony, 2012; De Jong and Mork, 2017; King et al, 2008; Mork et al, 2017; Ramirez, 2013). Interestingly, 5-HT₆ receptor antagonists may, at least in part, modify cognitive function by altering the morphology and function of hippocampal neuronal primary cilia (Chaumont-Dubel et al, 2019). Supporting this notion, “transgenic” Amyloid Precursor Protein (APP)/Presenilin 1 mice overexpressing β -amyloid show cognitive impairment in water maze, Y-maze, and fear-conditioning tasks, and 7 days 5-HT₆ antagonist treatment both recovered cognitive function and normalized cilia length (Hu et al, 2017). Together with findings that 5-HT₆ antagonists like SB-271046 reverse a palette of age-related cognitive defects in aged mice and rats (Callaghan et al, 2012; Da Silva Costa et al, 2009, 2011; Foley et al, 2004; Hirst et al, 2006), these observations are of particular relevance to their use in AD. 5-HT₆ antagonists also improve learning and memory deficits in neurodevelopmental models for cognitive dysfunction, such as isolation-reared rats (Fone, 2008). In other animal models, 5-HT₆ receptor antagonists act synergistically with AChE inhibitors to promote cognition, observations that prompted clinical studies of their adjunctive utilization in AD (De Jong and Mork, 2017; Khoury et al, 2018). As a final remark, care should be taken when considering the pharmacological actions of 5-HT₆ ligands in mice since several agents (like SB-258585 and Ro 04-6790) have lower affinity for mouse *vs* as compared to rat and human receptors: this is largely due to differences at residues 188 and 290 in transmembrane regions 5 and 6 of the 5-HT₆ receptor (Hirst et al, 2003).

Over ten years after discovery of selective antagonists, the first 5-HT₆ receptors agonists (such as WAY-181187 and E6801) emerged and, surprisingly, several groups found them to mimic antagonists in enhancing cognitive function in tasks of novel object recognition (Kendall et al, 2011), spontaneous alternation (Rychtyk, 2019), attentional set-shifting (Nikiforuk et al, 2013) and conditioned fear-motivated learning (Woods et al, 2012). Conversely, other labs did *not* find agonist-induced memory enhancement (Amodeo et al, 2018; Fone, 2008): indeed, WAY-181187 attenuated social recognition (Loiseau et al, 2008). Further, while 5-HT₆ agonists SB-271046-reversibly elicited increases in levels of mRNA encoding cytoskeleton-associated protein (Arc) in hippocampus, their elevation in frontal cortex was *reproduced* by SB-271046 rather than attenuated (de Foubert et al, 2007).

Several reasons may account for the apparent anomaly that agonists mimic some pro-cognitive effects of antagonists (Fone, 2008; De Jong and Mork, 2017). One hypothesis is that antagonists modulate function exclusively in pathways with a high serotonergic tone. In addition, agonists and antagonists may act *via* distinct signaling pathways. Another possibility is that 5-HT₆ agonists and antagonists alter the activity of *different*, spatially discrete populations of 5-HT₆ receptor. For example, agonists might directly activate 5-HT₆ receptors on cholinergic and/or glutamatergic neurones to promote ACh and glutamate release, whereas antagonists likely inhibit receptors on GABAergic interneurons to *indirectly* enhance the release of these neurotransmitters (Fone, 2008; Mork et al, 2017; De Jong and Mork, 2017). Finally, the relationship of 5-HT₆ receptor activity to cognitive function could show a bell-shaped relationship, modified in opposite directions by agonists compared to antagonists. These competing (but not mutually exclusive) explanations await further experimental evaluation.

As regards cellular substrates underlying the pro-cognitive actions of 5-HT₆ receptor antagonists, they are promiscuous in coupling to a large variety of signalling pathways (Chaumont-Dubel et al, 2019; Codony et al, 2011; Deraredj Nadim et al, 2016; Millan et al, 2008). 5-HT₆ receptors are coupled *via* Gs to generation of cAMP and activate adenylyl cyclase in a Gs-dependent manner, leading to recruitment of protein kinase A and cAMP-response binding element-1 ("CREB"), a prototypical lynch-pin of neuroplasticity. Blockade of CREB in GABAergic neurons might be involved in the effects of 5-HT₆ antagonists, but the role of CREB in the control of cognition by 5-HT₆ receptors is unlikely to be confined to this action (Codony et al, 2011; Deraredj Nadim et al, 2016; Millan et al, 2008; Teng et al, 2019). More recently 5-HT₆ receptors were shown to interact with cyclin-dependent kinase 5 (Cdk5) which regulates neurite outgrowth: alterations in Cdk5 activity in the hippocampus conceivably mediate changes in cilia morphology and hippocampal-dependent learning and memory (Chaumont-Dubel et al, 2019; Dayer et al, 2015; Duhr et al, 2014; Hu et al, 2019). Additional partners of 5-HT₆ receptors include Jun activation domain-binding protein-1 (Jab1) and the light chain 1 subunit of microtubule associated protein 1B (MAP1B) (Chaumont-Dubel et al, 2019; Kim et al, 2014; Liu et al, 2019; Yun et al, 2010). Their role in the control of cognition remains unclear, but one specific protein partner of 5-HT₆ receptors has been strongly implicated in the regulation of neuronal plasticity and cognition, mTOR (Bockaert and Marin, 2015; Mueed et al, 2018). In the frontal cortex, a physical interaction of the C-terminal domain of the 5-HT₆ receptor with the mTOR complex causes its phosphorylation-activation to impair cognition in the novel object recognition and social recognition tasks: these actions are prevented by the mTOR antagonist, rapamycin and by selective 5-HT₆ receptor antagonist (Fone et al, 2008; Loiseau et al, 2008; Meffre et al, 2012). mTOR activity is augmented in neonatal phencyclidine and isolation-rearing models of cognitive impairment, and the deficits are attenuated both by rapamycin and by 5-HT₆ receptor antagonists (Meffre et al, 2012). Furthermore, Dietary Restriction was suggested to promote hippocampal Long-Term Potentiation and memory by *negative* modulation of 5-HT₆ receptor mediated signaling (Teng et al, 2019). This action involved a role for mTOR as well as a NMDA receptor mediated induction of hippocampal pools of Brain-Derived Neurotrophic Factor (Teng et al, 2019). Regulation of hippocampal Brain-Derived Neurotrophic Factor expression may more generally be involved in the influence of both antagonists and agonists upon cognition and depressed mood (de Foubert et al, 2007; Rychtyk et al, 2019). Other mechanisms implicated in the pro-cognitive effects of 5-HT₆ receptor antagonists include the induction of neural cell adhesion molecule polysialylation in the entorhinal and perirhinal (Foley et al, 2008).

Despite this array of cellular mechanisms, it is unlikely that they represent the full picture of how 5-HT₆ receptors influence cognition. Further research is warranted to elucidate the molecular substrates underlying the pro-cognitive actions of 5-HT₆ antagonists, which may well differ between specific classes of neuron. This would likely provide insights into potentially innovative classes of multi-target agent and their clinical exploitation. In addition, as mentioned above, the precise significance of negative ligand efficacy and cognitive performance remains to be clarified as regards the actions of agonists and antagonists.

Regrettably, despite the impressive array of experimental data suggesting that 5-HT₆ antagonists exert pro-cognitive effects, clinical trials in AD - and schizophrenia - have not demonstrated sufficient therapeutic benefit to justify authorization, either alone or in association with AChE inhibitors (Atri et al, 2018; Maher-Edwards et al, 2015; Matsunaga et al, 2019; Wilkinson et al, 2014). A plethora of 5-HT₆ antagonists, including SB-742457 (intepirdine), SAM-760, A-964324, AVN-322, masupirdine, SYN-120, idalorpidine have, then, unfortunately failed to reach patients (De Jong and Mork, 2017; Ferrero et al, 2017; Khoury et al, 2018; Matsunaga et al, 2019; Wicke et al, 2015). This must surely vie with the collapse of Neurokinin1 antagonist programmes for depression (Millan et al, 2015; Rupniak and Kramer, 2017) as one of the most frustrating and unforeseen disappointments in modern psychopharmacological drug development. The reasons underlying the inability to concretize promising preclinical and Phase II data with 5-HT₆ antagonists are multifarious, discussed in the papers herewith cited, and embrace several issues underlying the more general failure of putative pro-cognitive agents to achieve therapeutic success in AD (see above). Most specifically, and in accordance with the core message of this paper, the potential utility of 5-HT₆ receptor antagonism for improving cognition in AD and other disorders may require exploitation in association with *additional* MOAs, either in combination or, preferentially, integrated into a single molecule.

5-HT₆ receptors as a foundation for multi-target therapies

As summarized above, enrichment of 5-HT₆ receptors in the cortex, hippocampus, basal ganglia and other regions, together with their influence on glutamatergic, cholinergic and GABAergic transmission, provides a neuronal framework for the broad-based influence of antagonists on cognition and mood. On the other hand, despite encouraging Phase II readouts, phase III investigations with highly *selective* 5-HT₆ antagonists have been disappointing. However, even discounting the many issues that have plagued trials of pro-cognitive agents in AD (*vide supra*), this is not to say that 5-HT₆ sites are irrelevant to the treatment of AD (Abbott and Dolgin, 2016; Millan, 2006; Bessalov et al, 2016). This would be a case of false logic in the same manner as declaring that 5-HT_{2A} receptors are irrelevant to the pathogenesis and management of schizophrenia on the basis that highly selective antagonists were not themselves effective in clinical trials alone: rather 5-HT_{2A} receptor blockade is an advantageous component of the multi-target profile of agents that likewise block dopamine D₂ and D₃ receptors (Meltzer, 2012).

Accordingly, it would be of interest to associate 5-HT₆ receptor blockade with other MOAs that favour the relief of cognitive dysfunction. In theory, this might be realised by either drug combinations or multi-target agents (Cummings et al, 2019 ; Millan, 2014; Sahoo et al; 2018). However, the latter strategy predominates, partly since polypharmacology is a particular concern in the elderly (Millan, 2014; Ravona-Springer and Davison, 2014). Further, no selective 5-HT₆ antagonists are currently on the market rendering their adjunctive use impossible. In fact, “atypical antipsychotics” like clozapine and olanzapine possess significant antagonist properties at 5-HT₆ receptors yet, as discussed elsewhere, their blockade of muscarinic, histamine-1 and α 1-adrenoceptors as well as D2 receptors interferes with any putative, pro-cognitive actions (Meltzer, 2012; Millan et al, 2012, 2016). This point underpins the need to focus on compounds displaying 5-HT₆ receptor antagonist properties plus one or two additional, well-defined and useful attributes, rather than generating ligands that indiscriminately interact with many receptor types. In practical terms, the most realistic approach is to design and search for dual-acting agents, while monitoring and amplifying rather than ignoring or discarding other beneficial pharmacological activities that may crop up unexpectedly. In any event, the avoidance of interactions triggering side-effects and directly interrupting pro-cognitive processes is obviously important.

As pointed out above, several clinical trials for AD were performed in patients treated with AChE inhibitors (“on top of”), most significantly those with idalorpidine where no arm with the drug alone was included in the Phase III study (Atri et al, 2018; Ferrero et al, 2017; Khoury et al, 2018; Matsunaga et al, 2019). Retrospectively it is easy to carp, but lack of information on the drug alone complicates interpretation of the failure to reach the primary outcome. It also raises the question of whether intrinsic, procognitive actions of 5-HT₆ antagonists alone might paradoxically have been *blunted* rather than enhanced due to long-term AChE inhibition (De Jong and Mork, 2017; Kennedy et al, 2018). While a pharmacokinetic interaction is unlikely and easily controlled for, there may have been pharmacological interference such as nicotinic receptor desensitization (see above). This is speculative, but the coupling of 5-HT₆ antagonism to AChE inhibition does not appear particularly attractive for multi-target ligands. Moreover, in developing “5-HT₆ plus” ligands, an important goal is not merely to provide more robust control of cognitive deficits but also, if possible, to counter the neuropsychiatric symptoms of AD (*vide supra*). The notion of generating multi-target 5-HT₆ ligands with additional *disease-modifying* properties is also briefly outlined below although, compared to other classes of potential therapy, 5-HT₆ antagonism as a starting point does not appear especially auspicious for course-alteration.

Thus, the emphasis here is on 5-HT₆ antagonism as a pivotal activity for improving the *symptoms* of AD - and possibly those of other neurodegenerative disorders. Relief of symptoms has, in view of clinical failures and a hugely-expanded range of options for attacking core pathophysiology, taken a back-seat in recent years (Scheltens, 2016; Stahl, 2018). However, to reiterate, for already-diagnosed patients with emerging and established dysfunction, alleviation of their symptoms is understandably their primary preoccupation, so maintaining “R and D” in this domain is more than justified.

Two examples of potential routes towards multi-target 5-HT₆ ligands are shown in **Figures 4 and 5**. As mentioned above, and exemplified here for social cognition, the mTOR inhibitor, rapamycin, blocks the

“amnesic” actions of the 5-HT₆ agonist, WAY181,187 and, more significantly it potentiates the pro-cognitive effects of the antagonist, SB258,585. This observation suggests scope for facilitating the improvement of cognition by 5-HT₆ blockade, potentially in association with mTOR inhibition. It has been previously shown that glutamatergic neurotransmission and NMDA/Glycine B receptors are involved in the pro-cognitive properties of 5-HT₆ antagonists (Codony et al, 2011; Fone et al, 2008), and the NMDA channel blocker, dizocilpine, duly prevented the actions of the 5-HT₆ antagonist, SB271,046, in the social recognition procedure. In addition, and again pointing to a multi-target 5-HT₆ plus mechanisms for restoring cognition in AD, the Glycine B co-agonist, D-Serine (Fossat et al, 2012; Ivanov and Mothet, 2019) enhanced the efficacy of SB271,046.

These findings, while clearly requiring extension, support the notion of multi-target 5-HT₆ blockade for AD. Amongst a range of dual-acting 5-HT₆ antagonist-based options currently under exploration, for reasons outlined below, the focus herein is on agents with complementary antagonist properties at D₃ receptors. However, prior to a detailed consideration of this strategy, the following paragraphs summarize progress with several other classes of multi-target 5-HT₆ ligand.

5-HT₆ receptor blockade: fusion with 5-HT₄ agonist, AChE inhibitory and other properties

In view of the opportunities for exploiting 5-HT₆ receptors as a fulcrum for the elaboration of multi-target agents, it is surprising that so little work has been undertaken. For example, one could imagine the association of 5-HT₆ receptor blockade with PAM properties at either AMPA receptors or specific subtypes of nicotinic receptor, or their combination with of histamine H₃ receptor blockade REF. Further, as indicated above, rapamycin potentiated the pro-cognitive properties of 5-HT₆ antagonists in rats, so mixed 5-HT₆ antagonists/mTOR inhibitors are conceivable (Chaumont-Dubel et al 2019; Meffre et al, 2012). Quite apart from the entrenched resistance on logistical grounds of most drug-discovery managers to challenging multi-target (*vs* comparatively straightforward, selective) drug discovery projects, the dearth of multi-target 5-HT₆ antagonists probably reflects the original conviction that *selective* 5-HT₆ antagonists would be clinically successful: there were few or no drug discovery programmes run in parallel with a view to finding 5-HT₆ antagonists with additional pharmacological properties. Ironically, the realisation that the clinical efficacy of *selective* 5-HT₆ antagonists is limited is now proving equally discouraging: it is being assumed, based on the *lack* of therapeutic efficacy of selective antagonists, that 5-HT₆ receptors are irrelevant (see above)! Thus, the handful of mechanisms outlined below represents only a sub-set of those in theory available for exploration. The focus is on concepts and pharmacological profile: readers are referred to the original papers cited below and to reviews for discussion (by experts) of the underlying chemistry (Zhang et al, 2019). In fact, the search for multi-target 5-HT₆ ligands advanced in parallel with efforts to find both selective and multi-target 5-HT₄ agonists and, in both cases, an association with AChE inhibition has attracted attention - despite reservations expressed above.

One early study cobbled together pharmacophores for both AChE and 5-HT₆ receptors to generate a centrally-active derivative of tacrine possessing well-balanced activities of around 10 - 30 nM both for 5-

HT6 receptors and for AChE and butyrylcholinesterase (Wieckowska et al, 2018). Subsequently, the same group reported a compound (“12”) that possessed marked antagonist activity at 5-HT6 receptors (K_i/K_b , 18/132 nM) and which also inhibited AChE and butyrylcholinesterase at comparable concentrations (IC_{50} values, 14 and 22 nM, respectively). Interestingly, it was also active, albeit at higher concentrations (1.27 μ M), in a (thioflavin) assay assessing inhibition of β -amyloid1-42 aggregation. Compound 12 showed reasonable blood-brain barrier penetration and - together with agents lacking a potentially hepatotoxic tacrine structure - it is an interesting starting point for further investigation of novel classes of multi-target 5-HT6 ligand (Wieckowska et al, 2018). While there remain concerns about potential cardiotoxic effects, the therapeutic use of 5-HT4 agonists for treating constipation suggests that clinically safe ligands are feasible (Lalut et al, 2017).

In parallel, originating in the chance discovery that the “selective” 5-HT4 partial agonist, RS67333 interacts with modest affinity with AChE, other groups have searched for 5-HT4R ligands that even more potently inhibit the activity of AChE, as exemplified by donecopride, a hybrid of RS67333 and donepezil (Lecoutey et al, 2014; Legay et al, 2015; Rochais et al, 2015). Donecopride has robust affinity for both 5-HT4 receptors (6.6 nM) and AChE (16 nM). Reflecting its 5-HT4 agonist properties, it promoted the non-amyloidogenic processing of APP (11 nM) leading to preferential release of soluble APP α and decreased formation of β -amyloid1-42. Further, donecopride was active in a novel object recognition test *in vivo* (Lecoutey et al, 2014; Rochais et al, 2015). It would be interesting to learn more about donecopride and related agents (Hughes et al, 2016; Legay et al, 2015).

It is hardly astonishing that efforts have been made to merge these strategies, and the first description of a combined 5-HT4 (5.3 nM) and 5-HT6 receptor ligand (219 nM) was made by Yahiaoui et al, in 2016. However, the highlighted ligand, “7m”, left considerable room for improvement. It had a substantial (40-fold) margin between these activities, it was also a potent ligand at 5-HT2A (330 nM) and 5-HT2C receptors (160 nM), and its ostensible “anti-amnesic” activity in a model of spontaneous alteration disrupted by scopolamine was, not to put too fine a point on it, marginal. Much more encouragingly, the same group reported the discovery of ligands possessing “triple” activity at 5-HT₄ receptors, 5-HT6 receptors and AChE. One of these “pleiotropic” compounds (“10”), moderated the deficits in performance elicited by scopolamine in a rat model of working memory (Hatat et al, 2019). Another line of study has focused on multi-target ligands that interact both with 5-HT6 receptors and with butyrylcholinesterase and that, in addition, possess anti-oxidant properties, in the hope of adding neuroprotective to pro-cognitive properties (Marcinkowska et al, 2019). Further work to attain compounds with well-balanced activities at these sites and functional activity *in vivo* would be desirable.

Very recently, another class of multi-target 5-HT6 receptor ligand has been described: putative, pro-cognitive agents interacting with both 5-HT6 and 5-HT2A receptors. Not unnaturally, these agents are primarily intended for the treatment of psychosis (Staron et al, 2019) but their potential relevance to AD is worth keeping in mind in view of a favourable influence upon sleep and psychosis by virtue of antagonist (inverse agonist) properties at 5-HT2A receptors (Ballard et al, 2018; Millan, 2006; Monti, 2010). Moreover, in a paper that appears to have been largely overlooked, an imaging study reported that the

“highly selective” 5-HT₆ antagonist, SB742,547, dose-dependently occupied 5-HT_{2A} receptors in the frontal cortex over a dose range only slightly higher than that seeing 5-HT₆ receptors in the hippocampus: intriguingly, doses that blocked both 5-HT₆ and 5-HT_{2A} receptors correlated to those putatively promoting cognition (Parker et al, 2012). While supporting interest in dual-acting 5-HT₆ and 5-HT_{2A} receptor antagonists for opposing cognitive impairment in AD, this paper raises questions about the design and interpretation of the clinical effects of « highly selective” 5-HT₆ antagonists in AD (see above).

Finally, in another line of investigation that similarly straddles therapy for both psychosis/schizophrenia and AD, agents that associate 5-HT₆ antagonism with partial agonist properties at D₂ receptors have been designed for the potential treatment of the behavioural symptoms and psychosis that characterise dementia, as well as the accompanying cognitive impairment (Kolakowski et al, 2015). The up-fronted ligand, “47” (5-HT₆, 1.0 nM and D₂, 6.3 nM) displayed antidepressant and anxiolytic properties in *aged* rats, but putative pro-cognitive actions have not as yet been described. Furthermore, equipotent activity was seen at a number of other sites including α 1-adrenoceptors and 5-HT_{1A} as well as D₄ receptors. While such actions are not necessarily deleterious, they hardly conform to the profile of a combined 5-HT₆ antagonist/D₂ partial agonist *per se*, a profile remaining to be described. In fact, compound 47 possessed high affinity for hD₃ receptors, neatly anticipating a consideration of combined 5-HT₆/D₃ receptor ligands below.

However, prior to this discussion, it is important to consider why D₃ receptors appear so attractive as candidate targets for integration with 5-HT₆ antagonist properties.

D3 receptor antagonists mimic 5-HT₆ antagonists in enhancing cognitive performance in a suite of preclinical procedures

By analogy to 5-HT₆ receptor antagonists, there is a rich body of evidence suggesting that D₃ receptor blockade is associated with improved cognitive performance (Leggio et al, 2016; Millan et al, 2012; Nakajima et al, 2013), with the perhaps decisive difference that D₃ receptor agonists (in distinction to 5-HT₆ agonists) act oppositely in consistently *interfering* with cognitive performance.

As regards D₂ (and D₁) receptors, their activation favours cognitive processes, whereas blockade exerts a deleterious influence - potent D₂ receptor antagonism likely interferes with any potentially beneficial influence of second-generation antipsychotics upon cognition in schizophrenia (Leggio et al, 2016; Millan et al, 2012; Watson et al, 2012). Conversely, stimulation of D₃ receptors has the opposite effect, being linked to a negative impact on cognition, whereas D₃ receptor antagonists enhance cognitive performance. This distinctive role of D₃ receptors, which parallels that of 5-HT₆ receptors, is underscored by a broad-based body of data from mice genetically deprived of D_{3R} and with selective D₃ vs D₂ antagonists. As reviewed elsewhere (Leggio et al, 2016; Millan and Brocco, 2008; Millan et al, 2010; Nakajima et al, 2013; Sokoloff, 2013), pro-cognitive actions of D₃ antagonists are expressed:

- in mice, rats and primates, upon single and repeated administration, in tests incorporating measures of attention, working memory, long-term memory and executive function, as well as procedural memory and conditioned learning, and in procedures monitoring social cognition, in particular social recognition (*op cit*);
- upon direct introduction of D3 ligands into specific brain regions, principally the frontal cortex, but with potential roles for other cortical zones (like the cingulate cortex) as well as the nucleus accumbens, midbrain and hippocampus (Chang et al, 2020; Choi et al, 2010; Cole et al, 2012; Glickstein et al, 2005; Guma et al, 2019; Loiseau and Millan, 2009; Papp et al, 2019; Watson et al, 2012).
- in subjects displaying ageing-related memory deficits, and in interaction with proteins implicated in the cognitive deficits of AD and other neurodegenerative disorders (D'Amico et al, 2013; Leggio et al, 2016; Micale et al, 2010; Nakajima et al, 2013; Xing et al, 2010).
- in animal models of CNS disorders like psychosis, depression and PD, and in procedures incorporating conditions of fear, chronic stress and ovarian hormone deprivation (Millan and Brocco, 2008; Nakajima et al, 2013; Leggio et al, 2016; Papp et al, 2017).

As regards the neural and cellular substrates implicated in the positive influence of D3 receptor blockade upon cognition, they remain to be fully clarified and lack of certainty concerning their precise cellular localization in frontal cortex complicates matters. In any event, there is neurochemical and functional evidence that, by analogy to 5-HT₆ receptors, D3 receptor stimulation may (over)activate mTOR in the FCX and other structures and hence interfere with cognitive processing (Cavalleri et al, 2018 ; Collo et al, 2014): this possibly reflects a direct, physical interaction of D3 receptors with cytoplasmic mTOR (Marin, P pers. comm.). Indeed, likewise mimicking 5-HT₆ receptors, rapamycin blunts the amnesic actions of D3 agonists, notably in tests of social cognition and novel object recognition (Watson, D and Dekeyne, A, unpub obs) (Leggio et al, 2016 ; Nakajima et al, 2013). It should be noted that, dependent on the cellular environment and duration of activation, D3 receptors may also *inhibit* mTOR (Barroso-Chinea et al, 2019). While no link between the latter findings and cognition has as yet been made, this observation underpins the notion that mTOR behaves something like a “Rheostat” with a set-point defining an optimal level of activity guaranteeing cognitive processes - both under *and* over activation may be unfavourable; this holds true for D3 as well as 5-HT₆ receptors - and presumably other upstream mechanisms (Bockaert and Marin, 2015; Teng et al, 2019). Roles for D3 receptor-Gi/o coupled cascades converging onto CREB, Mitogen Activated Protein Kinase and/or Glycogen Synthase Kinase3 β are also potentially implicated in the reinforcement of cognition by D3 antagonists (Chang et al, 2020; Collo et al, 2014; Cussac et al, 1999; Jiao et al, 2007; Millan et al, 2008a; Nakajima et al, 2013; Newman-Tancredi et al, 1998).

At the level of neurotransmitters, D3 antagonists promote the release of ACh in the frontal cortex, and may potentiate D-Serine gating of NMDA receptors, while synchronising circuits by virtue of their influence on GABA receptors (Millan et al, 2000, 2007, 2008b, 2016; Swant et al, 2008; Sokoloff et al, 2013; Watson et al, 2012). Induction of ACh release mirrors the effects of 5-HT₆ antagonists, and

reinforcement of signalling at NMDA receptors would be synergistic to enhancement of glutamatergic neurotransmission by 5-HT6 antagonists (see above). On the other hand, in contrast to 5-HT6 blockade, D3R antagonists do *not* affect extracellular levels of dopamine and noradrenaline in frontal cortex (De Jong and Mork, 2017; Millan et al, 2000; 2008b, 2016). There are, thus, both distinctive *and* convergent mechanisms for pro-cognitive properties for D3R compared to 5-HT6R antagonists.

From the above remarks, there is clearly a powerful body of evidence supporting the potential relevance of D3 receptor blockade to improvement of cognition in AD and other forms of dementia as well as Mild Cognitive Impairment and age-related cognitive deficits in general. Furthermore, there are many data more generally linking alterations in dopaminergic neurotransmission, and especially D2 and D3 receptors, with AD (Pan et al, 2019). An important caveat, shared with 5-HT6 antagonists, should be mentioned, however. Data from dedicated animal models for AD are awaited. This reflects the fact that, by analogy to 5-HT6 receptors, the majority of interest in D3 antagonists was initially directed towards their use in schizophrenia with AD crystallising as a valid therapeutic objective comparatively late in their lifetime of drug discovery and characterisation (de Bruin and Kruse, 2015; Gross et al, 2013; Miramai et al, 2018, Sokoloff et al, 2013; Millan et al, 2012, 2016; Watson et al, 2011).

Not to ignore this point, dual acting 5-HT6/D3 antagonists are evidently of considerable interest as potential agents for symptomatic control of AD. Other potential classes of multi-target D3 ligand, though not the central theme of this paper, are also briefly outlined below.

The concept of dual-acting 5-HT6/D3 antagonists: experimental support

Based on the above and other observations, it can be conjectured that co-joint blockade of 5-HT6 and D3 receptors may cooperatively promote cortically-integrated neurocognition and social cognition (**Figure 6**). Further, while D3R antagonism might moderate the occurrence of psychotic episodes, 5-HT6 receptor blockade may afford complementary anxio-depressive properties (Grychowska et al, 2016; Hirano et al, 2009; Wesolowska, 2010). Evidence for anti-epileptic properties of 5-HT6 antagonists is also of pertinence since the incidence of epilepsy and seizures is elevated in elderly patients with AD and other forms of dementia (Cretin, 2018; Lyou et al, 2019; Wang et al, 2015).

In this light, it is interesting to look at some experimental data where selective D3 and 5-HT6 antagonists have been combined in order to evaluate their co-joint influence upon extracellular levels of ACh in the frontal cortex and upon social recognition. As shown in **Figure 7**, (Millan et al, 2000, 2007; Mork et al, 2017), conjoint administration of SB271,046 (5-HT6 antagonist) and S33084 (D3 antagonist) exerts a more robust increase in extracellular levels of ACh in the frontal cortex of freely-moving rats than either drug alone. Considerable further study would be needed to determine whether this is a merely additive or in fact “synergistic” interaction. Ideally, such work should be undertaken in animal models for AD. Notwithstanding obvious limitations, the data are promising and are mirrored by studies of the co-administration of 5-HT6 and D3 antagonists in a model of social recognition. Both classes of compound elicit dose-dependent and robust procognitive actions in these models (Loiseau et al, 2008; Loiseau and

Millan, 2009) and, as shown in **Figure 8**, low, *subactive* doses given together collectively displayed procognitive properties. Again, the key word here is preliminary, and it would be of particular interest to evaluate how concurrent blockade of 5-HT₆ and D₃ receptors might influence cognitive deficits in mouse models of AD employing multiple readouts embracing, say, executive performance and working memory. Furthermore, exactly how 5-HT₆ and D₃ receptors interact to promote ACh release and cognition remains to be elucidated, but one possibility is a conjoint blunting of mTOR signalling (see above).

Another intriguing question as yet to be addressed is whether there may be a physical interaction between 5-HT₆ and D₃ receptors that would be relevant to their control of cognition. One obvious place to look would be cerebral structures involved in the control of cognition where they are both enriched, notably the FCX, though perhaps also in the limbic system involved in the emotional dimension of cognition, and even the cerebellum which plays a more prominent role in cognition than generally realized (Fone, 2008; Leggio et al, 2016; Li and Kuzhikanathil, 2012; Loiseau et al, 2008; Millan et al, 2012; Watson et al, 2012; Wagner and Luo, 2020). At the cellular level, both 5-HT₆ and D₃ receptors are localized on GABAergic neurons controlling the activity of cortical and cortico-subcortical networks, so this would be an interesting class of neuron to examine (Fone et al, 2008; Helboe et al, 2015; Leggio et al, 2019; Li and Kuzhikanathil, 2012; Millan et al, 2012; Swant et al 2008). Currently, despite the ability of 5-HT₆ and D₃ receptors to associate with other proteins (that influence cognition), and the propensity of D₃ receptors to form heterodimers with other types of G-protein coupled receptor, there does not appear to be any concrete (cellular or proteomic) support for the existence of 5-HT₆/D₃ heterodimers (Chaumont-Dubel et al, 2019; Deraredj Nadim et al, 2016; Hounsou et al, 2019; Leggio et al, 2019; Maggio et al, 2009; Marin et al, 2012; Missale et al, 2010). Of course, they may only pop up upon systematically being sought for.

Further work would be desirable and several questions remain, yet the above observations provide support for the concept that the fusion of 5-HT₆ and D₃ antagonist properties into a single distinctive structure may yield agents with a more powerful influence on impaired cognition in AD than selective compounds alone. Underpinning interest in such dual-acting agents, 5-HT₆ and D₃ receptor antagonists are distinctive in view of the virtual lack of on-target-driven, undesirable actions: in any case, shared positive actions should allow for an increase in therapeutic window *vs* putative undesirable effects triggered separately.

Identification and characterisation of mixed 5-HT₆/D₃ receptor antagonists

The reasoning and observations outlined above have prompted several groups to search for dual-acting 5-HT₆ /D₃ antagonists.

The first ligands described that possess robust affinities for both 5-HT₆ and D₃ sites were produced by GSK in the wake of a whole sequence of highly selective and well-characterised 5-HT₆ antagonists - including SB271,046 and SB285,585. One example of such a mixed ligand is SB737,050 (**Figure 9**) (Dupuis et al, 2008; Glennon et al, 2010). However, SB737,500 and related ligands still show high affinity for D₂ sites, and at that time were oriented towards schizophrenia. Moreover, they do not

seem to be very active *in vivo* and have not been pursued, possibly for strategic reasons that have little to do with pharmacology and therapeutics.

In a later series of studies, high affinity 5-HT₆ antagonists served as a starting point for structural modifications designed to introduce moieties that preferentially favoured interaction with D₃ over D₂ sites. (Saavedra et al, 2017). The compounds generated displayed fairly decent affinity for 5-HT₆ sites and encouraging D₃ over D₂ selectivity. However, as exemplified by compound 13, selectivity was limited, ligands were of only modest potency and - since they were racemic - it was not deemed useful to confirm that they behaved as genuine antagonists at 5-HT₆ and D₃ sites. Rather, chemistry was pursued resulting in further sets of ligands that present more robust affinities at 5-HT₆ and D₃ sites and more pronounced selective for D₃ over D₂ sites. One of these compounds has been described previously, “45”, and is shown in Figure 9 whereas another, S48475, is still under wraps for Intellectual Property reasons - its structure will be released in a primary article in the not too distant future (Ortuno, 2016). In any event, S48475 serves to illustrate a compound that behaves as an equi-potent antagonist at both h5-HT₆ (pK_i, 8.6) and hD₃ (pK_i, 8.5) vs hD₂ (pK_i, 6.8) sites and which possesses pro-cognitive properties *in vivo* in a test of social cognition disrupted by Scopolamine (**Figure 10**). Further, S48475 showed anxiolytic properties in a Vogel Conflict Test, presumably reflecting its 5-HT₆ antagonist properties (Figure 10). Finally, reflecting its preferential blockade of D₃ over D₂ receptors (25-fold higher affinity for the former), S48475 blunted amphetamine-induced locomotion without eliciting catalepsy (unpub obs), suggesting that it may be useful for counteracting psychosis in AD. S48475 and related compounds display low affinity for other classes of serotonin and dopamine receptor (Saavedra et al, 2018; unpub obs). Work is continuing on such ligands in order to identify solid clinical candidates, but the core point here is that it is indeed possible to build brain-penetrant and functionally-active ligands that possess balanced and potent activity at 5-HT₆ and D₃ receptors yet much lower affinity for D₂ receptors.

More recently, the neutral 5-HT₆ antagonist, “CPPQ”, was exploited as a novel template for the generation of mixed 5-HT₆ and D₃ antagonists in an independent laboratory (Grychowska et al, 2019). PZ-1643, the leading representative of this set of compounds, is depicted in Figure 9. It shows good and similar affinity for 5-HT₆ and D₃ receptors, behaving as an antagonist at D₃ receptors as determined employing cAMP (adenylyl cyclase) and other types of cellular assay. Interestingly, it behaves as a neutral antagonist at (constitutively active) 5-HT₆ sites in contrast to several selective agents which manifest inverse agonist properties (Dupuis et al, 2008; Grychowska et al, 2019). Affinities at other receptors examined, like 5-HT_{1A} and 5-HT_{2A}, were low. Moreover, this agent blocked the disruption by phencyclidine of novel objection recognition in rats (Grychowska et al, 2019). Intriguingly, further, it possessed neuroprotective properties in an astrocytic model of neurotoxicity *in vitro*, although the underlying mechanisms and relevance to degeneration in AD remain to be clarified. In any event, PZ-1643 and similar compounds provide a promising template for the development of novel classes of ligand possessing 5-HT₆ and antagonist D₃ properties, which are of potential utility for improving both the cognitive and neuropsychiatric symptoms of AD and other neurodegenerative disorders of aging.

Other potential classes of dual-acting D3 antagonist

The focus here is on 5-HT₆ receptors as a point of departure for the design of novel classes of multi-target agent, but D₃ receptors could themselves be exploited as a point of departure. Curiously, there does not appear to be much in the way of chemical activity around this objective in the framework of AD and other neurodegenerative disorders of aging (Cortes et al, 2016; Leggio et al, 2016 ; Miramai et al, 2015; Sokoloff, 2017). Nonetheless, as an incitement for such efforts, there is some - albeit very preliminary - evidence that the procognitive actions of D₃R antagonists can be potentiated by other classes of agent.

Thus, as shown in **Figure 11**, the pro-cognitive actions of S33084 in the novel object recognition procedure were potentiated by the metabotropic glutamatergic receptor (mGluR)-2 PAM, LY379,268 (Ikichi et al, 2013). These are only *initial* observations requiring consolidation and extension but it is interesting to note that a mGluR2 PAM similarly potentiated the actions of muscarinic M₁ and M₅ agonists as regards their ability to blunt the deleterious influence of the NMDA receptor channel blocker, dizocilpine, in tests of novel object recognition as well as delayed alternation (Cieslik et al, 2018). Supporting the notion of combining pharmacological activities, tested alone, LY379,268 - which is thought to moderate excessive hippocampal circuit activity in animal models of AD – did not restore cognitive function in mice overexpressing β -amyloid (Hascup et al, 2019). To reiterate the point made above, it is a pity that D₃ antagonists have not (to our knowledge) been evaluated in this and other animal models for AD: this would be desirable both alone and in association with mGluR2 PAMs, 5-HT₆ antagonists and other classes of potentially useful therapeutic ligand.

We have also found preliminary indications that selective D₁ agonists - prototypical pro-cognitive agents difficult to exploit clinically (Floresco, 2013; Jiao et al, 2007; Kim et al, 2015) - and D₃ antagonists reveal additive pro-cognitive actions in the social recognition test (Figure 11). It is not yet known how this interaction operates, but it may be of relevance that, mimicking D₃R antagonists, D₁R agonists stimulate the release of ACh in frontal cortex (Di Cara et al, 2007).

These initial observations, the broad range of options available, and the fact that D₃ receptor pharmacophores can be integrated with structures interacting with sites like 5-HT₆ receptors support the design of multi-target D₃ antagonists for countering the cognitive impairment of AD and other disorders: for example, Parkinson's disease, where D₃ receptor blockade itself favours the relief of motor dysfunction (Mela et al, 2010; Visanji et al 2009).

Potential disease-modifying properties of dual-acting agents?

As pointed out at the inception of this article, the strategies articulated herein are principally directed towards the improved symptomatic control of AD. Nonetheless, a word on a potential impact on the course of the disease itself is warranted.

This question has often been raised whether long-term treatment with agents possessing AChE inhibitory properties may be associated with “neuroprotective properties” and a slowing of disease progression. Despite some indications of reduced mortality in retrospective analyses for specific AChE inhibitors like donepezil or galantamine, unequivocal evidence that clinically-used doses of AChE inhibitors slow or prevent the evolution of AD in prospective trials has *not* been acquired (Bhattacharjee et al, 2019; Tricco et al 2018). As regards 5-HT₄ agonists, in view of their above-mentioned ability to impede the generation of β -amyloid from APP in experimental models (Lalut et al 2017), it would be particularly worth exploring this facet for combined 5-HT₄/AChE and 5-HT₆/5-HT₄ ligands. Curiously enough, mirroring the pro-cognitive actions of 5-HT₆ antagonists *and* agonists, there has been a report that they both counter the neurotoxic actions of β -amyloid fragments in neuronal cultures (Bokare et al, 2017). However, apart from a generalised suppression of Radical Oxygen Species, no MOA could be advanced. This remains, then an isolated observation but, surprisingly again, both a 5-HT₆ antagonist *and* an agonist were found to induce hippocampal expression of Brain-Derived Neurotrophic Factor. Like induction of hippocampal neurogenesis, this action might be favourable under conditions of a degenerating hippocampus but it is not a cipher for a “neuroprotective action” *per se* and the more obvious link is to cognition (Codnony et al, 2011; Rychtyk et al, 2019). Nonetheless, it is of interest that epileptic seizures induce 5-HT₆ expression in the hippocampus, and 5-HT₆ antagonists block both the accompanying disruption of cognition as well as neuronal apoptosis (Liu et al, 2019). Finally, inasmuch as this article has forwarded dual-acting 5-HT₆/D₃ ligands as agents for relieve of cognitive dysfunction in AD, it is worth noting that there is evidence for induction of hippocampus neurogenesis by blockade of D₃ receptors (Egeland et al, 2012).

On a rather different tack, 5-HT₆ receptors lie upstream of and stimulate mTOR, Cyclin-dependent Kinase 5 and Fyn kinases that play a role in Tau hyperphosphorylation (Chaumont-Dubel et al, 2019; Caccamo et al, 2013; Codony et al, 2011; Di Domenico et al, 2018; Meffre et al, 2012; Millan, 2017; Yun et al, 2007). Accordingly, while not neglecting cellular compartmentalization, it is not impossible that 5-HT₆ receptor blockade palliates Tau-driven pathophysiological mechanisms driving AD. Such agents would correspond to the previously-evoked notion of “hybrid” agents which, by virtue of their MOA, express comparatively rapid symptomatic effects that presage (and are neurally linked to) longer-term disease-modifying actions that impede the progression of the disorder (Millan et al, 2016).

Overall, despite some tantalising hints, the foundations for potential disease-modifying properties of dual-acting 5-HT₆/D₃ ligands and other classes of 5-HT₆ receptor-based agent are shaky, but they justify focussed evaluation in both cellular and *in vivo* models for AD, as well as Parkinson disease and other classes of neurodegenerative disorder.

General Discussion and future prospects

Several more general points arising from the above discussion merit brief commentary.

First, the development and characterisation of novel classes of multi-target agent for treating AD articulated around 5-HT₆ and D₃ receptors is still in its infancy and much work remains to be performed for their further validation, refinement and characterisation. Moreover, the classes of ligand presented herein are only a small subset of those that could, at least in theory, be designed and developed for improving the lives of people suffering from AD (**Figure 12**). As regards future clinical development, it will be important to sidestep past problems, errors and constraints (see above) encountered with selective 5-HT₆ antagonists. For example, we can highlight the crucial importance of establishing target engagement in patients at doses evaluated in clinical trials of efficacy. The availability of Positive Emission Tomography (PET) ligands for characterising drug interactions with D₆ and D₃ receptors in animals is of particular importance in this regard (Matuskey et al, 2016; Parker et al, 2012, 2015; Radhakrishnan et al, 2018; Tateno et al, 2018).

Second, genetics, imaging, biofluid and other classes of biomarker are greatly progressing the stratification of AD and the identification of target subpopulations patients best amenable to be improved by specific classes of therapeutic agent (Molinuevo et al, 2019). Expanding the repertoire of procedures for assessing cognitive and functional status in AD, from novel measures of cognitive function to remote digital monitoring should also prove informative (Gold et al, 2018; Kueper et al, 2018; Piau et al, 2019; Porcelli et al, 2019)

Third, logically enough, the present discussion focused on 5-HT₆ antagonist properties since the rationale is compelling and this approach has been pursued clinically. Nonetheless, as pointed out above, many “antagonists” behave as inverse agonists in cellular models, and the relevance of inverse agonist properties to the improvement of cognitive performance (or lack of effect) remains to be deciphered. It is also worth considering what might be the utility of multi-target 5-HT₆ *agonists* in light of above-discussed data suggesting that they could also, reflecting recruitment of neural circuits contrasting to those engaged by antagonists, promote cognition. An interesting parallel here is provided by α 7-nicotinic agonists (Verma et al, 2018). Most of the focus has been on PAMs, but they rapidly desensitize and *negative* allosteric modulators might palliate the β -amyloid driven hippocampal network (glutamatergic) hyperexcitability/hyperactivity that characterises early phases of AD (Zott et al, 2018) - though a very recent paper on conjoint blockade of α 7 and α 4 β 2 receptors questions this idea (Sun et al, 2019).

Fourth, while the present article has focussed on AD, we should evoke a potential role for 5-HT₆/D₃ antagonists for the amelioration of cognitive function and neuropsychiatric symptoms in other classes of neurodegenerative disorder of ageing. In addition, the potential evaluation of dual-acting 5-HT₆/D₃ antagonists in the control of the cognitive and other symptoms of schizophrenia - where neither class of agent alone may be sufficiently active - alone is justified (De Bruin and Kruse, 2016; Gross et al, 2013; Huang et al, 2015; Millan and Brocco, 2008; Nikiforuk, 2014; Takeuchi et al, 2019; Watson et al, 2011; Kotani et al, 2016). Interestingly, studies of receptor occupancy indicate that the antipsychotics, cariprazine (a partial D₃ agonist) and blonanserin, preferentially occupy D₃ over D₂ receptors *in vivo* (despite similar affinities), consistent with a beneficial influence on cognition, though this remains to be clinically proven (Baba et al, 2015; Girgis et al, 2019; Tateno et al, 2018). In addition to schizophrenia, the

potential use of 5-HT₆/D₃ antagonists for the improvement of neurocognitive performance, attention and social integration in autism and attention deficit hyperactivity disorder deserves consideration (Barth et al, 2013; Chang et al, 2020).

Finally, improved medication for controlling the cognitive, neuropsychiatric and other symptoms of AD and for impeding its progression would clearly be of immense importance. Nonetheless, mirroring the notion of multi-target agents, it is unlikely that any single drug would provide an ideal solution. The association of several classes of medication with other appropriate non-pharmacotherapeutic interventions will likely prove essential for the broad-based and effective treatment of the majority of people suffering from AD (Ngandu et al, 2016; Saito et al, 2019; Van den Brink et al, 2019).

Concluding comments

To conclude, it is important to forward multi-target strategies for symptomatic control of Mild Cognitive Impairment, AD, dementia and other neurodegenerative disorders of aging in parallel with increasingly intense efforts to find disease-modifying treatment. This currently stalled pursuit of therapies to alleviate the cognitive and other deficits of AD is important since, despite the impressive progress in knowledge of the pathology of AD, no panacea to stop its progression in the tens of millions of patients already hit by idiopathic AD is yet in the offing. It is certain that a whole arsenal of mechanistically-diverse, symptomatic and course-altering medications will be needed, in harmony with lifestyle changes and other types of intervention, to provide a broad-based palette of options for palliating the onset and impact of AD and other neurodegenerative disorders of aging. These efforts are being increasingly oriented around the concept of “Personalized” and “Precision” Medicine to prevent and treat AD. They should not, however, distract from the no less urgent imperative to address more universal risk factors for aging, brain and mental health such as pervasive metabolic and infectious disorders, climate change, environmental degradation, loss of biodiversity, poverty, inequality and urban decay which not infrequently strike the most vulnerable and less well-off communities first (Eid et al, 2019; Millan et al, 2015).

Acknowledgements

The authors would like to express their thanks to the following collaborators who were involved in work related to data presented: L Cistarelli, R Billiras, D Sicard, S Veiga, V Pasteau, G. De Nanteuil and D Dupuis. MJM would also like to thank M Gaillet and her team for their assiduous support in providing literature for consultation in the writing of this review. We also thank JM Rivet for assistance with the graphics.

Figure legends

Figure 1 An overview of the core features of Alzheimer disease.

The figure summarizes the major clinical symptoms of late onset, sporadic, non-familial AD, together with a broad spectrum of risk factors. There is considerable heterogeneity between patients, and the precise pattern of clinical deficits and neural anomalies evolves over time for an individual patient. The central image is of Auguste D, the first case of AD described by Alois Alzheimer in Frankfurt in 1901. As indicated, AD represents around 60-70% cases of dementia, with vascular dementias, dementia with Lewy bodies and other forms comprising the remaining patients. Some 5-10% cases of AD are autosomal dominant and attributable to disruption of genes encoding Presenilin (PSEN) 1 and PSEN2 or APP.

Figure 2 A schematic depiction of the paucity of agents for improving symptoms of AD compared to the rich panoply of options for major depression, itself a risk factor for AD.

As shown in the upper arrow, there has been a continuous supply of novel and mechanistically-distinct agents to treat major depression culminating most recently in esketamine for Treatment-Resistant Depression and brexanolone for Post-Menstrual Depression - which is not to ignore their (for some people/organisations prohibitively) high costs. In addition, cognitive-behavioural-psychosocial therapies are available as well as electroconvulsive therapy and various modes of brain stimulation. Conversely, only two classes of medication are available for AD, in addition (in the US) to an association of Donepezil and Memantine (Namzaric). Classes of medication; 1), Tricyclic; 2), Irreversible Monoamine Reuptake Inhibitor; 3), Preferential DA reuptake inhibitor; 4), Selective 5-HT reuptake inhibitor, 5), Glutamatergic modulator; 6), Reversible Monoamine Reuptake Inhibitor; 7), 5-HT/Noradrenaline reuptake inhibitor; 8), 5-HT_{2A/C}/α₂-adrenoceptor antagonist; 9), Preferential Noradrenaline reuptake inhibitor; 10), Melatonin agonist/5-HT_{2C} antagonist; 11), 5-HT_{1A} partial agonist/5-HT reuptake inhibitor; 12), Multi-target 5-HT receptor ligand/5-HT reuptake inhibitor; 13), Non-competitive blocker of NMDA receptors and 14), Allosteric modulator of GABA_A receptors. I), AChE inhibitor and II), Rapid kinetic, moderate potency, non-competitive NMDA receptor antagonist.

Figure 3 A schematic depiction of the convergence of serotonin and other classes of neurotransmitter modulating cognition in the frontal cortex.

The classical neurotransmitters depicted, as well as others, interact in the control of cognitive processes and other functions like mood and motor behaviour by virtue of cortico-cortical and cortico-subcortical circuits. Although the major focus to date has been on agents that target *individual* mechanisms rather than the interplay amongst them, this provides a template for association of serotonergic (5-HT₆) and dopaminergic (D₃) mechanisms as discussed herein (Figure 4). Note that interactions also occur in interconnected regions like the basal ganglia and hippocampus.

Figure 4 Influence of the mTOR inhibitor, rapamycin, on the amnesic and pro-cognitive properties of 5-HT6 agonists and antagonists, respectively in the social recognition test in rats.

As described previously (Meffre et al, 2012; Watson et al, 2012), T2-T1 represents the difference in exploration time of a juvenile by an adult rat in two 5 minutes sessions separated by 120 mins: after this period, in vehicle-treated adults, the younger rat has been forgotten so there is little difference in T2 and T1. Accordingly, an increase in this difference (high negative T2-T1 value) suggests improved retention of social recognition. Left panel: Rapamycin blocks the amnesic actions of the 5-HT6 agonist in the social recognition test in rats. The closed asterisk shows significance of the amnesic effect of WAY181,187 and the open asterisk depicts the significance of the blocking action of rapamycin against WAY181,187. Right panel: Rapamycin facilitates the pro-cognitive actions of a sub-active dose of the 5-HT6 antagonist, SB258,585. Closed asterisks show the significance of the potentiating action of rapamycin (Rap/SB) vs Veh/SB and Rap/Veh respectively. Data were analysed by ANOVA followed by Newman-Keul's test (*P< 0.05).

Figure 5 Interaction of the NMDA antagonist, dizocilpine, and of the NMDA/Glycine B agonist, D-Serine, with the 5-HT6 antagonist, SB271,046 in the social recognition test in rats.

See legend to Figure 4 for explanation of the methodology and the significance of T2-T1 (Watson et al, 2012). Left panel: Dizocilpine blocks the pro-cognitive properties of SB271,046. Right panel: D-Serine potentiates the pro-cognitive properties of a sub-active dose of SB271,046. Closed asterisks show the significance of the blocking action of dizocilpine action vs SB271,046 (Diz/SB vs Veh/SB) and of the potentiating actions of D-Serine for SB271,046 (D-Ser/SB vs Veh/SB), respectively. Data were analysed by ANOVA followed by Newman-Keul's test (*P< 0.05).

Figure 6 A conceptual framework for the association of 5-HT6 and D3 antagonist properties for the more effective symptomatic treatment of AD.

The notion of association is principally for a single agent that possess dual 5-HT6 and D3>D2 antagonist properties but it could also apply to the combination of selective agents. As outlined in the text, 5-HT6 and D3 antagonist properties may promote cognition by both common (such as increased release of ACh and suppression of overactive mTOR) and independent mechanisms. While blockade of 5-HT6 receptors has been associated with anxiolytic and anti-depressive properties, antagonism of D3 receptors may be useful in the alleviation of psychosis.

Figure 7 Additive increases in extracellular levels of acetylcholine in dialysates of frontal cortex of freely-moving rats by administration of S33084 and SB271,046, selective antagonists at D3 and 5-HT6 receptors, respectively.

Extracellular levels of acetylcholine were determined in the absence of cholinesterase inhibitors in the frontal cortex of freely-moving rats by HPLC coupled to electrochemical detection, as described previously, and expressed in relation to basal values (2.2 ± 0.4 pg/20ul, defined as 100%) (Millan et al, 2007). The arrows indicate the time of injection of D3 and 5-HT6 antagonists, respectively. The closed asterisks indicate the significance of differences for Veh/S33084 and Veh/SB271,046 vs Veh/Veh values, and the hashed sign indicates the significance of differences between S33084/SB271,046 and Veh/SB271,046 values. Data were analysed by ANOVA followed by Newman-Keul's test (*P < 0.05).

Figure 8 Additive improvements in social recognition by administration of S33084 and SB271,046 or SB258,585, selective antagonists at D3 and 5-HT6 receptors, respectively.

See legend to Figure 4 for explanation of the methodology and the significance of T2-T1 (Watson et al, 2012). Both D3 and 5-HT6 antagonists promote social cognition in a dose-dependent manner in this procedure (Loiseau et al, 2008; Loiseau and Millan, 2009), but here were evaluated separately and together at sub-effective doses. The asterisks indicate statistical significance of differences between S33084/SB271,046 vs veh/SB271,046 and of S33084/SB228,585 vs veh/SB258,585 values. Data were analysed by ANOVA followed by Newman-Keul's test (*P < 0.05).

Figure 9 Chemical structures of several published agents possessing dual antagonist properties at D3 and 5-HT6 receptors.

SB737,050 has high affinity for 5-HT6 receptors and balanced affinity at D3 and D2 receptors: it has served as a useful starting point for generating dual-acting 5-HT6/D3 agents. Compounds 13b and the more potent 45 have more balanced affinities for 5-HT6 and D3 *versus* D2 receptors.

Figure 10 Functional profile of an agent, S48475, possessing high affinity for both 5-HT6 and D3 vs D2 receptors.

Upper panels: Antagonist properties of the mixed 5-HT6/D3>D2 receptor antagonist, S48475, in cellular procedures for actions at h5-HT6, D3 and D2 receptors - it was inactive alone (not shown). Left lower panel, pro-cognitive actions of S48475 in a test of social recognition (blockade of disruption by the muscarinic antagonist, scopolamine (1.25 mg/kg)) in rats. Right lower panel: anxiolytic properties in the

Vogel conflict test - disinhibition of punished responding in rats. Data were analysed by ANOVA followed by Newman-Keul's test (* $P < 0.05$).

Figure 11 Additive actions in tests of cognitive function of the selective dopamine D3 antagonist, S33084, given together with the mGluR2 PAM, LY379,268, or with the dopamine D1 agonist, SKF 81297.

Top Panel. As described previously (Watson et al, 2012), the D2 score reflects the increase in performance in the novel object recognition test in a second *vs* first exposure to the object. The open asterisks indicate the significance of differences between Veh/S33084 and Veh/Veh values, and between LY379268/S33084 and LY379268/Veh values. The closed asterisk indicates the significance of differences between LY379268/S33084 and Veh/S33084 values. Data were analysed by ANOVA followed by Newman-Keul's test (* $P < 0.05$). Bottom Panel. See legend to Figure 4 for explanation of T2-T1. Both D3 antagonists and D1 agonists promote social cognition in a dose-dependent manner in the social recognition procedure but were here evaluated separately and together at sub-effective doses (Di Cara et al, 2007; Millan et al, 2007). The closed asterisk indicates the significance of differences between SKF81297/S33084 and Veh/SKF81297 values. Data were analysed by ANOVA followed by Newman-Keul's test (* $P < 0.05$).

Figure 12 A schematic illustration of potential classes of dual-acting ligand articulated around 5-HT6 and D3 receptors as hubs.

Agonist, agonist and ant, antagonist. The interlinked targets could be mutually modulated by dual-acting agents, but the notion of drugs that interact with more than two of these sites should also be considered. The "pyramid" is non-exhaustive, based on available pharmacological studies and/or chemical structures and could be expanded to additional classes of mechanisms that potentially promote cognition and oppose neuropsychiatric symptoms in AD and neurodegenerative disorders of aging.

References

- Abbott A., Dolgin E. 2016 Nature. Failed Alzheimer's trial does not kill leading theory of disease. 540,15-16.
- Alam S., Lingenfelter K.S., Bender A.M., Lindsley C.W.. 2017 Classics in Chemical Neuroscience: Memantine. ACS Chem Neurosci. 20, 1823-1829.
- Amodeo, D.A., Peterson, S., Pahua, A., Posadas, R., Hernandez, A., Hefner, E., Qi, D., Vega, J., 2018. 5-HT₆ receptor agonist EMD386088 impairs behavioral flexibility and working memory. Behav. Brain Res. 349, 8-15.
- Aparicio-Nava L, Tellez R, Gonzalez R, Liy-Salmeron G, 2019 Meneses A. Intrahippocampal administration of 5-HT₆ receptor drugs on memory consolidation and amnesia protocols; Behav Brain Res. 359, 378-385.
- Arendash G., Cao C., Abulaban H., Baranowski R., Wisniewski G., Becerra L., Andel R., Lin X., Zhang X., Wittwer D., Moulton J., Arrington J., Smith A. 2019 A Clinical Trial of Transcranial Electromagnetic Treatment in Alzheimer's Disease: Cognitive Enhancement and Associated Changes in Cerebrospinal Fluid, Blood, and Brain Imaging. J Alzheimers Dis.71, 57-82.
- Armato U., Chakravarthy B., Pacchiana R., Whitfield J.F. 2013 Alzheimer's disease: an update of the roles of receptors, astrocytes and primary cilia (review). Int J Mol Med. 31, 3-10.
- Atri, A., Frolich, L., Ballard, C., Tariot, P.N., Molinuevo, J.L., Boneva, N., Windfeld, K., Raket, L.L., Cummings, J.L., 2018. Effect of idalopirdine as adjunct to cholinesterase inhibitors on change in cognition in patients with alzheimer disease: three randomized clinical trials. J. Am. Med. Assoc. 319, 130–142.
- Baba, S, Enomoto, T, Horisawa, T, Hashimoto, T, One, M 2015 Blonanserin extensively occupies rat dopamine D3 receptors at antipsychotic dose range. J Pharmacol Sci 127, 326-331.
- Ballard C., Banister C., Khan Z., Cummings J., Demos G., Coate B., Youakim J.M., Owen Rv, Stankovic S., ADP Investigators. 2018 Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study. Lancet Neurol. 17, 213-222.
- Barroso-Chinea P, Luis-Ravelo D, Fumagallo-Reading F, Castro-Hernandez J, Salas-Hernandez J, Rodriguez-Nuñez J, Febles-Casquero A, Cruz-Muros I, Afonso-Oramas D, Abreu-Gonzalez P, Moratalla

R, Millan MJ, Gonzalez-Hernandez T. 2019 DRD3 (dopamine receptor D3) but not DRD2 activates autophagy through MTORC1 inhibition preserving protein synthesis. *Autophagy*. 2019 Oct 2:1-17.

Barth, V, Need, AB, Tzavara, ET, Giros, B, Overshiner, C, Gleason, SD, Wade, M, Johansson, AM, Perry, K, Nomikos, GG, Witkin, JM 2013 In vivo occupancy of dopamine D3 receptors by antagonists produces neurochemical and behavioral effects of potential relevance to attention-deficit-hyperactivity disorder. *J Pharmacol Exp Ther* 344, 501-510.

Belgacem YH, Borodinsky LN. 2017 CREB at the crossroads of activity-dependent regulation of nervous system development *Adv Exp Med Biol*. 2017; 1015:19-39.

Bernard K., Gouttefangeas S., Bretin S., Galtier S., Robert P., Holthoff-Detto V., Cummings J., Pueyo M. 2019 A 24-week double-blind placebo-controlled study of the efficacy and safety of the AMPA modulator S47445 in patients with mild to moderate Alzheimer's disease and depressive symptoms. *Alzheimers Dement (N Y)*. 5, 231-240.

Bespalov A., Steckler T., Altevogt B., Koustova E., Skolnick P., Deaver D., Millan M.J., Bastlund J.F., Doller D., Witkin J., Moser P., O'Donnell P., Ebert U., Geyer M.A., Prinssen E., Ballard T., Macleod M. 2016 Failed trials for central nervous system disorders do not necessarily invalidate preclinical models and drug targets. *Nat Rev Drug Discov*. 15, 516-520.

Bhattacharjee S., Patanwala A.E., Lo-Ciganic W.H., Malone D.C., Lee J.K., Knapp S.M., Warholak T., Burke W.J. 2019 Alzheimer's disease medication and risk of all-cause mortality and all-cause hospitalization: A retrospective cohort study. *Alzheimers Dement (N Y)*. 5, 294-302.

Birks J.S., Harvey R.J. 2018 Dozenepil for dementia. *Cochrane Database Syst Rev*. Jun 18;6:CD001190.

Bockaert, J., Marin, P., 2015. mTOR in brain physiology and pathologies. *Physiol. Rev.* 95, 1157–1187.

Bokare A. M., Praveenkumar A. K., Bhonde M., Nayak Y., Pal R., Goel R. 2017 5-HT₆ Receptor Agonist and Antagonist Against β -amyloid-Peptide-Induced Neurotoxicity in PC-12 Cells. *Neurochem Res* 42, 1571-1579

Boland B., Yu W.H., Corti O., Mollereau B., Henriques A., Bezard E., Pastores G.M., Rubinsztein D.C., Nixon R.A., Duchon M.R., Mallucci G.R., Kroemer G., Levine B., Eskelinen E.L., Mochel F., Spedding M., Louis C., Martin O.R., Millan M.J. 2018. Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing. *Nat Rev Drug Discov*. 17, 660-688

- Brailov, I., Bancila, M., Brisorgueil, M.J., Miquel, M.C., Hamon, M., Verge, D., 2000. Localization of 5-HT(6) receptors at the plasma membrane of neuronal cilia in the rat brain. *Brain Res.* 872, 271–275.
- Brodsky, M., Lesiak, A.J., Croicu, A., Cohenca, N., Sullivan, J.M., Neumaier, J.F., 2017. 5-HT6 receptor blockade regulates primary cilia morphology in striatal neurons. *Brain Res.* 1660, 10–19.
- Caccamo, A., Magri, A., Medina, D.X., Wisely, E.V., Lopez-Aranda, M.F., Silva, A.J., Oddo, S., 2013. mTOR regulates tau phosphorylation and degradation: implications for Alzheimer's disease and other tauopathies. *Aging Cell* 12, 370–380.
- Callaghan C.K., Hok V., Della-Chiesa A., Virley D.J., Upton N., O'Mara S.M. 2012 Age-related declines in delayed non-match-to-sample performance (DNMS) are reversed by the novel 5HT6 receptor antagonist SB742457. *Neuropharmacology.* 63, 890-897.
- Cavalleri L., Merlo Pich E., Millan M.J., Chiamulera C., Kunath T., Spano P.F., Collo G. 2018 Ketamine enhances structural plasticity in mouse mesencephalic and human iPSC-derived dopaminergic neurons via AMPAR-driven BDNF and mTOR signaling. *Mol Psychiatry,* 812-823
- Chang C.H., Lane H.Y., Lin C.H. 2018 Brain Stimulation in Alzheimer's Disease. *Front Psychiatry.* 2018 May 22;9:201
- Charnay, Y., Leger, L., 2010. Brain serotonergic circuitries. *Dialogues Clin. Neurosci.* 12, 471–487.
- Chasioti D., Yan J., Nho K., Saykin A.J. 2019 Progress in Polygenic Composite Scores in Alzheimer's and Other Complex Diseases. *Trends Genet* 35, 371-382.
- Chaumont-Dubel S., Dupuy V., Bockaert J., Bécamel C., Marin P. 2019 The 5-HT₆ receptor interactome: New insight in receptor signaling and its impact on brain physiology and pathologies. *Neuropharmacology.* Nov 1:107839.
- Choi J.K., Mandeville J.B., Chen Y.I., Grundt P., Sarkar S.K., Newman A.H., Jenkins B.G. 2010 Imaging brain regional and cortical laminar effects of selective D3 agonists and antagonists. *Psychopharmacology (Berl)* 212, 59-72
- Christidi F., Migliaccio R., Santamaría-García H., Santangelo G., Trojsi F. 2018. Social Cognition Dysfunctions in Neurodegenerative Diseases: Neuroanatomical Correlates and Clinical Implications *Behav Neurol.* Apr 26;2018:1849794.

- Cieślak P., Domin H., Chocyk A., Gruca P., Litwa E., Płoska A., Radulska A., Pelikant-Małecka I., Brański P., Kalinowski L., Wierońska J.M. 2019 Simultaneous activation of mGlu₂ and muscarinic receptors reverses MK-801-induced cognitive decline in rodents. *Neuropharmacology*. Nov 27;107866.
- Codony, X., Vela, J.M., Ramirez, M.J., 2011. 5-HT(6) receptor and cognition. *Curr. Opin.Pharmacol*. 11, 94–100.
- Collo G, Cavalleri L, Spano P. 2014 Structural plasticity in mesencephalic dopaminergic neurons produced by drugs of abuse: critical role of BDNF and dopamine. *Front Pharmacol*. 2014 Nov 25;5:259.
- Coombs I.D., Soto D., McGee T.P., Gold M.G., Farrant M., Cull-Candy S.G. 2019 Homomeric GluA2(R) AMPA receptors can conduct when desensitized. *Nat Commun*. Sep 20;10(1):4312.
- Cortés A., Moreno E., Rodríguez-Ruiz M., Canela E.I., Casadó V. 2016 Targeting the dopamine D3 receptor: an overview of drug design strategies. *Expert Opin Drug Discov*. 11, 641-664.
- Creese B., Da Silva M.V., Johar I., Ballard C. 2018 The modern role of antipsychotics for the treatment of agitation and psychosis in Alzheimer's disease. *Expert Rev Neurother*.18, 461-467.
- Cretin B. 2018 Pharmacotherapeutic strategies for treating epilepsy in patients with Alzheimer's disease. *Expert Opin Pharmacother* 19, 1201-1209.
- Cummings J. 2019 The Role of Biomarkers in Alzheimer's Disease Drug Development. *Adv Exp Med Biol*. 1118, 29-61
- Cummings J.L., Tong G., Ballard C. 2019 Treatment Combinations for Alzheimer's Disease: Current and Future Pharmacotherapy Options. *J Alzheimers Dis*. 67, 779-794.
- Cunnane S.C., Trushina E., Morland C., Prigione A., Casadesus G., Andrews Z.B., Beal F., Bergersen L.H., Brinton R.D., de la Monte S., Eckert A., Harvey J.Z., Jeggo R., Jhamandas J.H., Kann O., Mannoury la Cour C., Martin W.F., Mithieux G., Moreira P.I., Murphy M.P., Nave K.A. Nuriel T. Olié S., Saudou F., Mattson M.P., Swerdlow R.H., Millan M.J. 2020. Brain energy rescue: an emerging concept for new therapeutics in neurodegenerative disorders of aging, *Nature Rev Drug Discovery*, in press.
- Cussac D., Newman-Tancredi A., Pasteau V., Millan M.J. 1999 Human dopamine D(3) receptors mediate mitogen-activated protein kinase activation via a phosphatidylinositol 3-kinase and an atypical protein kinase C-dependent mechanism. *Mol Pharmacol*. 56, 1025-1030.
- D'Amico A.G., Castorina A., Leggio G.M., Drago F., D'Agata V 2013. Hippocampal neurofibromin and amyloid precursor protein expression in dopamine D3 receptor knock-out mice following passive avoidance conditioning. *Neurochem Res*. 38, 564-572.
- Darvesh S. 2016 Butyrylcholinesterase as a Diagnostic and Therapeutic Target for Alzheimer's Disease. *Curr Alzheimer Res*. 13,1173-1177
- Da Silva Costa-Aze V., Dauphin F, Boulouard M. 2011 Serotonin 5-HT6 receptor blockade reverses the age-related deficits of recognition memory and working memory in mice. *Behav Brain Res*. 222,134-140.

Da Silva Costa V., Duchatelle P., Boulouard M., Dauphin F. 2009 Selective 5-HT₆ receptor blockade improves spatial recognition memory and reverses age-related deficits in spatial recognition memory in the mouse. *Neuropsychopharmacology*. 34, 488-500.

Dayer, A.G., Jacobshagen, M., Chaumont-Dubel, S., Marin, P., 2015. 5-HT₆ receptor: a new player controlling the development of neural circuits. *ACS Chem. Neurosci*. 6, 951–960.

Deardorff W.J., Grossberg G.T. 2019 Behavioral and psychological symptoms in Alzheimer's dementia and vascular dementia. *Handb Clin Neurol*.165, 5-32.

de Bruin, N.M., Kruse, C.G., 2015. 5-HT₆ receptor antagonists: potential efficacy for the treatment of cognitive impairment in schizophrenia. *Curr. Pharmaceut. Des*. 21, 3739–3759.

de Freitas Silva M, Dias KST, Gontijo VS, Ortiz CJC, Viegas C Jr. 2018 Multi-Target Directed Drugs as a Modern Approach for Drug Design Towards Alzheimer's Disease: An Update. *Curr Med Chem*. 25, 3491-3525.

de Foubert, G., O'Neill, M. J., Zetterstrom, T. S., 2007. Acute onset by 5-HT(6)-receptor activation on rat brain brain-derived neurotrophic factor and activity-regulated cytoskeletal-associated protein mRNA expression. *Neuroscience* 147, 778-785.

de Jong, I.E.M., Mork, A., 2017. Antagonism of the 5-HT₆ receptor - preclinical rationale for the treatment of Alzheimer's disease. *Neuropharmacology* 125, 50–63.

Deraredj Nadim, W., Chaumont-Dubel, S., Madouri, F., Cobret, L., De Tauzia, M.L., Zajdel, P., Benedetti, H., Marin, P., Morisset-Lopez, S., 2016. Physical interaction between neurofibromin and serotonin 5-HT₆ receptor promotes receptor constitutive activity. *Proc. Natl. Acad. Sci. U. S. A*. 113, 12310–12315.

Di Cara B., Panayi F., Gobert A, Dekeyne A., Sicard D., De Groote L., Millan M.J. 2007 Activation of dopamine D1 receptors enhances cholinergic transmission and social cognition: a parallel dialysis and behavioural study in rats. *Int J Neuropsychopharmacol*. 10, 383-399.

Di Domenico, F., Tramutola, A., Foppoli, C., Head, E., Perluigi, M., Butterfield, D.A., 2018. mTOR in Down syndrome: role in Amyloid and tau neuropathology and transition to Alzheimer disease-like dementia. *Free Radic. Biol. Med*. 114, 94–101.

Dou KX, Tan MS, Tan CC, Cao XP, Hou XH, Guo QH, Tan L, Mok V, Yu JT. Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer's disease: a network meta-analysis of 41 randomized controlled trials *Alzheimers Res Ther*. 2018 Dec 27;10(1):126.

Drummond E., Wisniewski T. 2017 Alzheimer's disease: experimental models and reality. *Acta Neuropathol*. 133, 155-175

- Duhr, F., Deleris, P., Raynaud, F., Seveno, M., Morisset-Lopez, S., Mannoury la Cour, C., Millan, M.J., Bockaert, J., Marin, P., Chaumont-Dubel, S., 2014. Cdk5 induces constitutive activation of 5-HT₆ receptors to promote neurite growth. *Nat. Chem. Biol.* 10, 590–597.
- Dupuis D.S., Mannoury la Cour C., Chaput C., Verrière L., Lavielle G., Millan M.J. 2008 Actions of novel agonists, antagonists and antipsychotic agents at recombinant rat 5-HT₆ receptors: a comparative study of coupling to G alphas. *Eur J Pharmacol.* 588, 170-177.
- Egeland M., Zhang X., Millan M.J., Mocaer E, Svenningsson P. Pharmacological or genetic blockade of the dopamine D3 receptor increases cell proliferation in the hippocampus of adult mice. *J Neurochem.* 123, 811-823.
- Eid A., Mhatre I., Richardson J.R. 2019 Gene-environment interactions in Alzheimer's disease: A potential path to precision medicine. *Pharmacol Ther.* 199, 173-187.
- Eskenazi D., Brodsky M., Neumaier J.F. 2015 The 5-HT₆ receptor interactome: New insight in receptor signaling and its impact on brain physiology and pathologies. *Neuroscience* 299, 97-106.
- Ferrero, H., Solas, M., Francis, P.T., Ramirez, M.J., 2017. Serotonin 5-HT₆ receptor antagonists in alzheimer's disease: therapeutic rationale and current development status. *CNS Drugs* 31, 19–32.
- Floresco S. B. 2013 Prefrontal dopamine and behavioral flexibility: shifting from an "inverted-U" toward a family of functions. *Front Neurosci.* Apr 19;7:62
- Foley A.G., Hirst W.D., Gallagher H.C., Barry C., Hagan J.J., Upton N., Walsh F.S., Hunter A.J., Regan C.M. 2008 The selective 5-HT₆ receptor antagonists SB-271046 and SB-399885 potentiate NCAM PSA immunolabeling of dentate granule cells, but not neurogenesis, in the hippocampal formation of mature Wistar rats. *Neuropharmacology.* 54, 1166-1174
- Foley A.G., Murphy K.J., Hirst W.D., Gallagher H.C., Hagan J.J., Upton N., Walsh F.S., Regan C.M. 2004 The 5-HT(6) receptor antagonist SB-271046 reverses scopolamine-disrupted consolidation of a passive avoidance task and ameliorates spatial task deficits in aged rats. *Neuropsychopharmacology.* 29, 93-100.
- Fone, K. C. F., 2008. An update on the role of the 5-hydroxytryptamine(6) receptor in cognitive function. *Neuropharmacology* 55, 1015-1022.
- Fossat P., Turpin FR, Sacchi S, Dulong J, Shi T, Rivet JM, Sweedler JV, Pollegioni L, Millan MJ, Olié SH, Mothet JP 2012 Glial D-serine gates NMDA receptors at excitatory synapses in prefrontal cortex. *Cereb Cortex* 22, 595-606.
- Francis P.T., Parsons C.G., Jones R.W. 2012 Rationale for combining glutamatergic and cholinergic approaches in the symptomatic treatment of Alzheimer's disease. *Expert Rev Neurother.* 12, 1351-1365.

Gaubert S., Raimondo F., Houot M., Corsi M.C., Naccache L., Diego Sitt J., Hermann B. Oudiette D., Gagliardi G., Habert M.O., Dubois B., De Vico Fallani F., Bakardjian H., Epelbaum S. 2019 EEG evidence of compensatory mechanisms in preclinical Alzheimer's disease. Alzheimer's Disease Neuroimaging Initiative. *Brain*. 142, 2096-2112.

Girgis, RR, Slifstein, M, D'Souza, D, Lee, Y, Periclou, A, Ghahramani, P, Laszlovsky, I, D'Urgam, S, Asham, N, Nabulsi, N, Huang, Y, Carso, RE, Kiss, B, Kapas, M, Abi-Dargham, A, Rakhit, A. 2019 Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11)C]-(+)-PHNO. *Psychopharmacology* 233, 3503-3512.

Glennon R.A., Siripurapu U., Roth B.L., Kolanos R., Bondarev M.L., Sikazwe D., Lee M., Dukat M. 2010 The medicinal chemistry of 5-HT₆ receptor ligands with a focus on arylsulfonyltryptamine analogs. *Curr Top Med Chem*. 10, 579-595.

Glickstein S.B., Desteno D.A., Hof P.R., Schmauss C. 2005 Mice lacking dopamine D2 and D3 receptors exhibit differential activation of prefrontal cortical neurons during tasks requiring attention. *Cereb Cortex*. 15, 1016-1024.

Gold M, Amatniek J, Carrillo MC, Cedarbaum JM, Hendrix JA, Miller BB, Robillard JM, Rice JJ, Soares H, Tome MB, Tarnanas I, Vargas G, Bain LJ, Czaja SJ 2018 Digital technologies as biomarkers, clinical outcomes assessment, and recruitment tools in Alzheimer's disease clinical trials. *Alzheimers Dement* 24, 234-242.

Gross G., Wicke K., Drescher K.U. 2013 Dopamine D₃ receptor antagonism-still a therapeutic option for the treatment of schizophrenia. *Naunyn Schmiedebergs Arch Pharmacol*. 386; 155-166.

Guma, Rochetti, J, Devenyi, GA, Tanti, A, Mathieu, AP, Lerch, JP, Elgbeili, G, Courcot, B, Mechawar, N, Chakravarty, MM, Giros, B 2019 Role of D3 dopamine receptors in modulating neuroanatomical changes in response to antipsychotic administration. *Sci Rep* May 24;9(1):7850.

Grychowska, K., Chaumont-Dubel, S., Kurczab, R., Koczurkiewicz, P., Deville, C., Krawczyk, M., Pietrus, W., Satala, G., Buda, S., Piska, K., Drop, M., Bantreil, X., Lamaty, F., Pekala, E., Bojarski, A.J., Popik, P., Marin, P., Zajdel, P., 2019. Dual 5-HT₆ and D3 receptor antagonists in a group of 1H-Pyrrolo[3,2-c]quinolines with neuroprotective and procognitive activity. *ACS Chem. Neurosci*. 10, 3183–3196.

Grychowska, K., Satala, G., Kos, T., Partyka, A., Colacino, E., Chaumont-Dubel, S., Bantreil, X., Wesolowska, A., Pawlowski, M., Martinez, J., Marin, P., Subra, G., Bojarski, A.J., Lamaty, F., Popik, P., Zajdel, P., 2016. Novel 1H-Pyrrolo[3,2-c]quinolone based 5-HT₆ receptor antagonists with potential

application for the treatment of cognitive disorders associated with alzheimer's disease. *ACS Chem. Neurosci.* 7, 972–983.

Hascup K.N., Britz J., Findley C.A., Tischkau S., Hascup E.R. 2019 LY379268 Does Not Have Long-Term Procognitive Effects nor Attenuate Glutamatergic Signaling in A β PP/PS1 Mice. *J Alzheimers Dis.* 68, 1193-1209.

Hatat, B., Yahiaoui, S., Lecoutey, C., Davis, A., Freret, T., Boulouard, M., Claeysen, S., Rochais, C., Dallemagne, P., 2019. A novel in vivo anti-amnesic agent, specially designed to express both acetylcholinesterase (AChE) inhibitory, serotonergic subtype 4 receptor (5-HT₄R) agonist and serotonergic subtype 6 receptor (5-HT₆R) inverse agonist activities, with a potential interest against alzheimer's disease. *Front. Aging Neurosci.* 11, 148.

Helboe, L., Egebjerg, J., de Jong, I.E., 2015. Distribution of serotonin receptor 5-HT₆ mRNA in rat neuronal subpopulations: a double in situ hybridization study. *Neuroscience* 310, 442–454.

Henry J.D., von Hippel W., Molenberghs P., Lee T., Sachdev P.S. 2016 Clinical assessment of social cognitive function in neurological disorders. *Nat Rev Neurol.* 12, 28-39.

Hirano K., Piers T.M., Searle K.L., Miller N.D., Rutter A.R., Chapman PF. 2009 Procognitive 5-HT₆ antagonists in the rat forced swimming test: potential therapeutic utility in mood disorders associated with Alzheimer's disease. *Life Sci.* 84, 558-562.

Hirst, W. D., Abrahamsen, B., Blaney, F. E., Calver, A. R., Aloj, L., Price, G. W., Medhurst, A. D., 2003. Differences in the central nervous system distribution and pharmacology of the mouse 5-hydroxytryptamine-6 receptor compared with rat and human receptors investigated by radioligand binding, site-directed mutagenesis, and molecular modeling. *Mol Pharmacol* 64, 1295-1308.

Hirst W.D., Stean T.O., Rogers D.C., Sunter D., Pugh P., Moss S.F. 2006 SB-399885 is a potent, selective 5-HT₆ receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models. *Eur J Pharmacol.* 553,109–119.

Hornung, J.P., 2003. The human raphe nuclei and the serotonergic system. *J. Chem. Neuroanat.* 26, 331–343.

Hounsou, C, Margather, JF, Oueslati, N, Belhocine A, Dupuis E, Thomas C, Mann A, Ilien B, Rognan D, Trinquet E, Hibert M, Pin JP, Bonnet D, Durroux T. 2015 Time-resolved FRET binding assay to investigate hetero-oligomer binding properties: proof of concept with dopamine D1/D3 heterodimer. *ACS Chem Biol*;10, 466-474.

- Howard R., Liu K.Y. 2019 Questions EMERGE as Biogen claims aducanumab turnaround. *Nat Rev Neurol*. Nov 29. doi: 10.1038/s41582-019-0295-9.
- Hu, L., Wang, B., Zhang, Y., 2017. Serotonin 5-HT₆ receptors affect cognition in a mouse model of Alzheimer's disease by regulating cilia function. *Alzheimer's Res. Ther.* 9, 76.
- Huang M., Kwon S., Oyamada Y., Rajagopal L., Miyauchi M. Meltzer H. Y. 2015 Dopamine D₃ receptor antagonism contributes to blonanserin-induced cortical dopamine and acetylcholine efflux and cognitive improvement. *Pharmacol Biochem Behav.* 138, 49-57.
- Hughes R.E., Nikolic K., Ramsay R.R. 2016 One for All? Hitting Multiple Alzheimer's Disease Targets with One Drug. *Front Neurosci*. 2016. Apr 25;10:177.
- Ikichi H., Kaku A., Karasawa J., Chaki S. 2013 Stimulation of metabotropic glutamate (mGlu) 2 receptor and blockade of mGlu1 receptor improve social memory impairment elicited by MK-801 in rats. *J Pharmacol Sci.* 122, 10-16.
- Isaacson RS, Ganzer CA, Hristov H, Hackett K, Caesar E, Cohen R, Kachko R, Meléndez-Cabrero J, Rahman A, Scheyer O, Hwang MJ, Berkowitz C, Hendrix S, Mureb M, Schelke MW, Mosconi L, Seifan A, Krikorian R. 2018 The clinical practice of risk reduction for Alzheimer's disease: A precision medicine approach. *Alzheimers Dement.* 14, 1663-1673.
- Ivanov A.D., Mothet J.P. 2019 The plastic d-serine signaling pathway: Sliding from neurons to glia and vice-versa. *Neurosci Lett.* 689, 21-25.
- Jiao H., Zhang L., Gao F., Lou DC, Zhang J., Xu M. 2007 Dopamine D(1) and D(3) receptors oppositely regulate NMDA- and cocaine-induced MAPK signaling via NMDA receptor phosphorylation. *J Neurochem.* 103, 840-848.
- Joe E., Ringman J.M. 2019 Cognitive symptoms of Alzheimer's disease: clinical management and prevention. *BMJ* Dec 6;367:l6217.
- Kandiah N., Pai M.C., Senanarong V., Looi I., Ampil E., Park K.W., Karanam A.K., Christopher S.. 2017. Rivastigmine: the advantages of dual inhibition of cetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia. *Clin Interv Aging* 12, 697-707.
- Kann O The interneuron energy hypothesis: Implications for brain disease. 2016 *Neurobiol Dis* Jun;90:75-85.
- Kendall, I., Slotten, H.A., Codony, X., Burgueno, J., Pauwels, P.J., Vela, J.M., Fone, K.C., 2011. E-6801, a 5-HT₆ receptor agonist, improves recognition memory by combined modulation of cholinergic and glutamatergic neurotransmission in the rat. *Psychopharmacology (Berlin)* 213, 413–430.

- Kennedy R.E., Cutter G.R., Fowler M.E., Schneider L.S. 2018 Association of Concomitant Use of Cholinesterase Inhibitors or Memantine With Cognitive Decline in Alzheimer Clinical Trials: A Meta-analysis. *JAMA Netw Open*. 2018 Nov 2;1(7):e184080.
- Khoury, R., Grysman, N., Gold, J., Patel, K., Grossberg, G.T., 2018. The role of 5-HT₆ receptor antagonists in Alzheimer's disease: an update. *Expert Opin. Investig. Drugs* 27, 523–533.
- Kim Y.C., Alberico S.L., Emmons E., Narayanan N.S. 2015 New therapeutic strategies targeting D1-type dopamine receptors for neuropsychiatric disease. *Front Biol (Beijing)*. 2015 Jun;10(3):230-238.
- Kim, S.H., Kim, D.H., Lee, K.H., Im, S.K., Hur, E.M., Chung, K.C., Rhim, H., 2014. Direct interaction and functional coupling between human 5-HT₆ receptor and the light chain 1 subunit of the microtubule-associated protein 1B (MAP1B-LC1). *PLoS One* 9, e91402.
- King, M. V., Marsden, C. A., Fone, K. C. F., 2008. A role for the 5-HT_{1A}, 5-HT₄ and 5-HT₆ receptors in learning and memory. *Trends in Pharmacological Sciences* 29, 482-492.
- King, M. V., Sleight, A. J., Woolley, M. L., Topham, I. A., Marsden, C. A., Fone, K. C. F., 2004. 5-HT₆ receptor antagonists reverse delay-dependent deficits in novel object discrimination by enhancing consolidation - an effect sensitive to NMDA receptor antagonism. *Neuropharmacology* 47, 195-204.
- Kohnomi, S and Konishi, S 2015 Multiple actions of a D₁ dopamine receptor agonist, PD128907, on GABAergic inhibitory transmission between medium spiny neurons in mouse nucleus accumbens shell. *Neurosci Lett* 300, 17-21.
- Kończakowski M., Marcinkowska M., Bucki A., Śniecikowska J., Pawłowski M., Kazek G., Siwek A., Jastrzębska-Więsek M., Partyka A., Wasik A., Wesołowska A., Mierzejewski P, Bienkowski P 2015 Novel 5-HT₆ receptor antagonists/D2 receptor partial agonists targeting behavioral and psychological symptoms of dementia. *Eur J Med Chem*. 92,221-35.
- Kotani M., Enomoto T., Murai T., Nakako T., Iwamura Y., Kiyoshi A., Matsumoto K., Matsumoto A., Ikejiri M., Nakayama T., Ogi Y., Ikeda K. 2016 The atypical antipsychotic blonanserin reverses (+)-PD-128907- and ketamine-induced deficit in executive function in common marmosets. *Behav Brain Res*. 305, 212-217.
- Kowal N.M., Ahring P.K., Liao V.W.Y., Indurta D.C., Harvey B.S., O'Connor S.M., Chebib M., Olafsdottir E.S., Balle T. 2018 Galantamine is not a positive allosteric modulator of human $\alpha 4\beta 2$ or $\alpha 7$ nicotinic acetylcholine receptors. *Br J Pharmacol*. 175, 2911-2925.
- Kowalski K., Mulak A 2019 Brain-Gut-Microbiota Axis in Alzheimer's Disease. *J Neurogastroenterol Motil*. Jan 25, 48-60.

Kubo M., Kishi T., Matsunaga S., Iwata N. 2015 Histamine H3 Receptor Antagonists for Alzheimer's Disease: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. *J Alzheimers Dis* 48, 667-671.

Kueper JK, Speechley M, Montero-Odasso M. 2018 The Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog): Modifications and Responsiveness in Pre-Dementia Populations. A Narrative Review. *J Alzheimers Dis*. 63, 423-444.

Lanctôt K.L., Amatniek J., Ancoli-Israel S., Arnold S.E., Ballard C., Cohen-Mansfield J., Ismail Z., Lyketsos C., Miller D.S., Musiek E., Osorio R.S., Rosenberg P.B., Satlin A., Steffens D., Tariot P., Bain .L.J., Carrillo M.C., Hendrix J.A., Jurgens H., Boot B. 2017 Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms. *Alzheimers Dement (N Y)*. Aug 5;3(3):440-449.

Lalut, J., Karila, D., Dallemagne, P., Rochais, C., 2017. Modulating 5-HT4 and 5-HT6 receptors in Alzheimer's disease treatment. *Future Med. Chem.* 9, 781–795.

Lecoutey C., Hedou D., Freret T., Giannoni P., Gaven F., Since M., Bouet V., Ballandonne C., Corvaisier S., Malzert Fréon A., Mignani S., Cresteil T., Boulouard M., Claeysen S., Rochais C., Dallemagne P. 2014 Design of donecopride, a dual serotonin subtype 4 receptor agonist/acetylcholinesterase inhibitor with potential interest for Alzheimer's disease treatment. *Proc Natl Acad Sci U S A*. 111, E3825-3830.

Legay R., Boulouard M., Claeysen S., Dallemagne P. 2015 Novel multitarget-directed ligands (MTDLs) with acetylcholinesterase (AChE) inhibitory and serotonergic subtype 4 receptor (5-HT4R) agonist activities as potential agents against Alzheimer's disease: the design of donecopride. *J Med Chem*. 58, 3172-3187

Leggio G.M., Bucolo C., Platania C.B., Salomone S., Drago F. 2016. Current drug treatments targeting dopamine D3 receptor. *Pharmacol Ther*. 165,164-177.

Leggio, GM Torrisi SA, Mastrogiacomo R, Mauro D Chisari M, Devroye C, Scheggia D, Nigro M, Geraci F², Pintori N, Giurdanella G, Costa L, Bucolo C, Ferretti V, Sortino MA, Ciranna L, De Luca MA, Mereu M, Managò F, Salomone S, Drago F, Papaleo, F 2019 The epistatic interaction between the dopamine D3 receptor and dysbindin-1 modulates higher-order cognitive functions in mice and humans. *Mol Psychiatry* 2019 Sep 6.

Lesiak, A.J., Brodsky, M., Cohenca, N., Croicu, A.G., Neumaier, J.F., 2018. Restoration of physiological expression of 5-HT6 receptor into the primary cilia of null mutant neurons lengthens both primary cilia and dendrites. *Mol. Pharmacol*. 94, 731-742.

Leuzy A., Chiotis K., Lemoine L., Gillberg P.G., Almkvist O., Rodriguez-Vieitez E., Nordberg A. 2019 Tau PET imaging in neurodegenerative tauopathies-still a challenge. *Mol Psychiatry*. 24, 1112-1134.

- Li, Y., Kuzhikandathil, EV 2012 Molecular characterization of individual D3 dopamine receptor-expressing cells isolated from multiple brain regions of a novel mouse model. *Brain Struct Funct* 217,809-833.
- Liu, C., Wen, Y., Huang, H., Lin, W., Huang, M., Lin, R., Ma, Y., 2019. Over-expression of 5-HT6 receptor and activated jab-1/p-c-jun play important roles in pilocarpine-induced seizures and learning-memory impairment. *J. Mol. Neurosci.* 67, 388–399.
- Loiseau, F., Dekeyne, A., Millan, M.J., 2008. Pro-cognitive effects of 5-HT6 receptor antagonists in the social recognition procedure in rats: implication of the frontal cortex. *Psychopharmacology (Berlin)* 196, 99–104.
- Loiseau F., Millan M.J. 2009 Blockade of dopamine D(3) receptors in frontal cortex, but not in sub-cortical structures, enhances social recognition in rats: similar actions of D(1) receptor agonists, but not of D(2) antagonists. *Eur Neuropsychopharmacol.* 19, 23-33.
- Lopez OL, Kuller LH. 2019 Epidemiology of aging and associated cognitive disorders: Prevalence and incidence of Alzheimer's disease and other dementias. *Handb Clin Neurol.* 167, 139-148.
- Lyou H.J., Seo K.D., Lee J.E., Pak H.Y., Lee J.H. 2019. Association of Alzheimer's Disease with the Risk of Developing Epilepsy: a 10-Year Nationwide Cohort Study *Dement Neurocogn Disord.* 17, 156-162.
- Maggio, R, Aloisi, G, Silvano, E Rossi, M, Millan, MJ 2009 Heterodimerization of dopamine receptors: new insights into functional and therapeutic significance. *Parkinsonism Relat Disord* 15 Suppl 4:S2-7.
- Maher-Edwards, G., Watson, C., Ascher, J., Barnett, C., Boswell, D., Davies, J., Fernandez, M., Kurz, A., Zanetti, O., Safirstein, B., Schronen, J.P., Zvartau-Hind, M., Gold, M., 2015. Two randomized controlled trials of SB742457 in mild-to-moderate Alzheimer's disease. *Alzheimers Dement (N Y)* 1, 23–36.
- Maramai, S, Gemma, S, Borgi, S, Campiani, G, Butini, S, Stark, H, Brindisi, M 2015 Dopamine D3 receptor antagonists as potential therapeutics for the treatment of neurological diseases. *Front Neurosci.* 2016 Oct 5;10:451.
- Marazziti D, Baroni S, Pirone A, Giannaccini G, Betti L, Schmid L, Vatteroni E, Palego L, Borsini F, Bordi F, Piano I, Gargini C, Castagna M, Catena-Dell'osso M, Lucacchini A. 2012 Distribution of serotonin receptor of type 6 (5-HT₆) in human brain post-mortem. A pharmacology, autoradiography and immunohistochemistry study. *Neurochem Res.* 37, 920-927.
- Marcinkowska M., Bucki A., Panek D., Siwek A., Fajkis N., Bednarski M., Zygmunt M., Godyń J., Del Rio Valdivieso A., Kotańska M., Kołaczkowski M., Więckowska A. 2019 Anti-Alzheimer's multitarget-

directed ligands with serotonin 5-HT₆ antagonist, butyrylcholinesterase inhibitory, and antioxidant activity. *Arch Pharm (Weinheim)*. Jul;352(7):e1900041. doi: 10.1002/ardp.201900041.

Marin, P., Becamel, C., Dumuis, A., Bockaert, J., 2012. 5-HT receptor-associated protein networks: new targets for drug discovery in psychiatric disorders? *Curr. Drug Targets* 13, 28-52.

Matsunaga, S., Fujishiro, H., Takechi, H., 2019. Efficacy and safety of idalopirdine for Alzheimer's disease: a systematic review and meta-analysis. *Int Psychogeriatr* 31, 1627-1633.

Matsunaga S., Kishi T., Iwata N. 2014 Combination therapy with cholinesterase inhibitors and memantine for Alzheimer's disease: a systematic review and meta-analysis. *Int J Neuropsychopharmacol* 18, 18(5). pii: 115.

Matuskey D., Worhunksy P., Correa E., Pittman B., Gallezot J. D., Nabulsi N., Ropchan J., Sreeram V., Gudepu R., Gaiser E., Cosgrove K., Ding Y. S., Potenza M. N., Huang Y., Malison R. T., Carson R. E. 2016 Age-related changes in binding of the D2/3 receptor radioligand [(11)C](+)PHNO in healthy volunteers. *Neuroimage* 130, 241-247.

McArdle R., Morris R., Wilson J., Galna B., Thomas A.J., Rochester L. 2017 What Can Quantitative Gait Analysis Tell Us about Dementia and Its Subtypes? A Structured Review *J Alzheimers Dis.* 60,1295-1312.

McClam T.D, Marano C.M., Rosenberg P.B., Lyketsos C.G. 2015. Interventions for Neuropsychiatric Symptoms in Neurocognitive Impairment Due to Alzheimer's Disease: A Review of the Literature. *Harv Rev Psychiatry.* 23, 377-393.

McShane R., Westby M.J., Roberts E., Minakaran N., Schneider L., Farrimond L.E., Maayan N., Ware J., Debarros J. 2019 Memantine for dementia. *Cochrane Database Syst Rev.* Mar 20;3:CD00315.

Meffre, J., Chaumont-Dubel, S., Mannoury la Cour, C., Loiseau, F., Watson, D.J., Dekeyne, A., Seveno, M., Rivet, J.M., Gaven, F., Deleris, P., Herve, D., Fone, K.C., Bockaert, J., Millan, M.J., Marin, P., 2012. 5-HT(6) receptor recruitment of mTOR as a mechanism for perturbed cognition in schizophrenia. *EMBO Mol. Med.* 4, 1043–1056.

Mela F., Millan M.J., Brocco M., Morari M. 2010 The selective D(3) receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect L-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned rats. *Neuropharmacology.* 58, 528-536.

Meltzer H.Y. 2012 Serotonergic mechanisms as targets for existing and novel antipsychotics. *Handb Exp Pharmacol.* 212,87-124.

Micale V., Cristino L., Tamburella A., Petrosino S., Leggio G.M., Di Marzo V., Drago F. 2010 Enhanced cognitive performance of dopamine D3 receptor "knock-out" mice in the step-through passive-avoidance test: assessing the role of the endocannabinoid/endovanilloid systems. *Pharmacol Res.* 61, 531-536.

Millan M.J. 2006 Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application. *Pharmacol Ther.* 110, 135-370.

Millan, M.J., 2008 The discovery and development of pharmacotherapy for psychiatric disorders: A critical survey of animal and translational models and perspectives for their improvement pp 1-57. In: *Animal and Translational Models for CNS Drug Discovery* pp 483. Elsevier Amsterdam, 2008.

Millan M.J. 2014 On 'polypharmacy' and multi-target agents, complementary strategies for improving the treatment of depression: a comparative appraisal. *Int J Neuropsychopharmacol.* 17, 1009-1037

Millan M.J. 2017 Linking deregulation of non-coding RNA to the core pathophysiology of Alzheimer's disease: An integrative review. *Prog Neurobiol.* 156, 1-68.

Millan, M.J., Agid, Y., Brune, M., Bullmore, E.T., Carter, C.S., Clayton, N.S., Connor, R., Davis, S., Deakin, B., DeRubeis, R.J., Dubois, B., Geyer, M.A., Goodwin, G.M., Gorwood, P., Jay, T.M., Joels, M., Mansuy, I.M., Meyer-Lindenberg, A., Murphy, D., Rolls, E., Saletu, B., Spedding, M., Sweeney, J., Whittington, M., Young, L.J., 2012. Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. *Nat. Rev. Drug Discov.* 11, 141–168.

Millan M.J., Brocco M. 2008 Cognitive impairment in schizophrenia: a review of developmental and genetic models, and procognitive profile of the optimised D(3) 4 D(2) antagonist, S33138. *Therapie* 63, 187-229.

Millan M.J., Buccafusco J.J., Loiseau F., Watson D.J., Decamp E., Fone K.C. 2010. The dopamine D(3) receptor antagonist, S33138, counters cognitive impairment in a range of rodent and primate procedures. *Int J Neuropsychopharmacol* 13, 1035–1051.

Millan M.J., Di Cara B., Dekeyne A., Panayi F., De Groote L., Sicard D. et al (2007). Selective blockade of dopamine D(3) versus D(2) receptors enhances frontocortical cholinergic transmission and social memory in rats: a parallel neurochemical and behavioural analysis. *J Neurochem* 10, 1047–1061.

Millan M.J., Gobert A., Newman-Tancredi A., Lejeune F., Cussac D., Rivet J.M (2000). S33084, a novel, potent, selective, and competitive antagonist at dopamine D-3-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR 218, 231 and L741,626. *J Pharmacol Exp Ther* 293, 1048–1062.

Millan M.J., Goodwin G.M., Meyer-Lindenberg A., Ove Ögren S. 2015 Learning from the past and looking to the future: Emerging perspectives for improving the treatment of psychiatric disorders. *Eur Neuropsychopharmacol.* 25,599-656.

Millan M.J., Loiseau F., Dekeyne A., Gobert A., Flik G., Cremers T.I., Rivet J.M., Sicard D., Billiras R., Brocco M. 2008a S33138 (N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1] benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenyl]-acetamide), a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: III. Actions in models of therapeutic activity and induction of side effects *J Pharmacol Exp Ther.* 324, 1212-1226.

Millan, M.J., Marin, P., Bockaert, J., Mannoury la Cour, C., 2008b. Signaling at G-protein coupled serotonin receptors: recent advances and future research directions. *Trends Pharmacol. Sci.* 29, 454–464.

Millan M.J., Rivet J.M., Gobert A. 2016 The frontal cortex as a network hub controlling mood and cognition: Probing its neurochemical substrates for improved therapy of psychiatric and neurological disorders. *J Psychopharmacol.* 30,1099-1128.

Millan, M.J., Svenningsson, P., Ashby Jr., C.R., Hill, M., Egeland, M., Dekeyne, A., Brocco, M., Di Cara, B., Lejeune, F., Thomasson, N., Munoz, C., Mocaer, E., Crossman, A., Cistarelli, L., Girardon, S., Job, L., Veiga, S., Gobert, A., 2008c. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenyl]acetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent. II. A neurochemical, electrophysiological and behavioral characterization in vivo. *J. Pharmacol. Exp. Ther.* 324, 600–611.

Missale, C, Fiorentini, C, Collo, G, Spano, P 2010 The neurobiology of dopamine receptors: evolution from the dual concept to heterodimer complexes. *J Recept Signal Transduct Res* 30, 347-354.

Molinuevo J.L., Ayton S., Batrla R., Bednar M.M., Bittner T., Cummings J., Fagan A.M., Hampel H., Mielke

M.M., Mikulskis A., O'Bryant S., Scheltens P., Sevigny J., Shaw L.M., Soares H.D., Tong G., Trojanowski J.Q., Zetterberg H., Blennow K. 2018 Current state of Alzheimer's fluid biomarkers. *Acta Neuropathol.* 136, 821-853.

Monti, JM. 2010 Serotonin 5-HT_{2A} receptor antagonists in the treatment of insomnia: present status and future prospects. *Drugs Today (Barc).* 46, 183-193.

Mørk A., Russell R. V., de Jong I. E., Smagin G. 2017 Effects of the 5-HT₆ receptor antagonist idalopirdine on extracellular levels of monoamines, glutamate and acetylcholine in the rat medial prefrontal cortex. *Eur J Pharmacol.* 799, 1-6.

- Mueed, Z., Tandon, P., Maurya, S.K., Deval, R., Kamal, M.A., Poddar, N.K., 2018. Tau and mTOR: the hotspots for multifarious diseases in alzheimer's development. *Front. Neurosci.* 12, 1017.
- Mullane K., Williams M. 2019 Preclinical Models of Alzheimer's Disease: Relevance and Translational Validity. *Curr Protoc Pharmacol.* Mar;84(1):e57.
- Nakajima S., Gerretsen P., Takeuchi H., Caravaggio F., Chow T., Le Foll B., Mulsant B., Pollock B., Graff-Guerrero A. 2013 The potential role of dopamine D₃ receptor neurotransmission in cognition. *Eur Neuropsychopharmacol.* 23, 799-813.
- Neuner S.M., Heuer S.E., Huentelman M.J., O'Connell K.M.S., Kaczorowski C.C. 2019 Harnessing Genetic Complexity to Enhance Translatability of Alzheimer's Disease Mouse Models: A Path toward Precision Medicine *Neuron.* 101, 399-341.
- Newman-Tancredi A., Cussac D., Audinot V., Pasteau V., Gavaudan S., Millan M.J. 1999. G protein activation by human dopamine D₃ receptors in high-expressing Chinese hamster ovary cells: A guanosine-5'-O-(3-[³⁵S]thio)- triphosphate binding and antibody study *Mol Pharmacol.* 55, 564-574.
- Ngandu T., Lehtisalo J., Solomon A., Levälähti E., Ahtiluoto S., Antikainen R., Bäckman L., Hänninen T., Jula A., Laatikainen T., Lindström J., Mangialasche F., Pajananen T., Pajala S., Peltonen M., Rauramaa R., Stigsdotter-Neely A., Strandberg T., Tuomilehto J., Soininen H., Kivipelto M. 2015 A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. *Lancet.* 385, 2255-2263.
- Nikiforuk, A., 2014. The procognitive effects of 5-HT₆ receptor ligands in animal models of schizophrenia. *Rev. Neurosci.* 25, 367–382.
- Nikiforuk, A., Fijal, K., Potasiewicz, A., Popik, P., Kos, T., 2013. The 5-hydroxytryptamine (serotonin) receptor 6 agonist EMD 386088 ameliorates ketamine-induced deficits in attentional set shifting and novel object recognition, but not in the prepulse inhibition in rats. *J. Psychopharmacol.* 27, 469–476.
- Ortuno, J.C., Discovery of dopaminergic D₃ receptor antagonists with potent 5HT₆ affinity. RICT 2016: 52nd International Conference on Medicinal Chemistry. CAEN, July 6-8, 2016.
- Oyama A, Takeda S, Ito Y, Nakajima T, Takami Y, Takeya Y, Yamamoto K, Sugimoto K, Shimizu H, Shimamura M, Katayama T, Rakugi H, Morishita R. 2019 Novel Method for Rapid Assessment of Cognitive Impairment Using High-Performance Eye-Tracking Technology. *Sci Rep.* 2019 Sep 10;9(1):12932.
- Paouri E., Georgopoulos S. 2019 Systemic and CNS Inflammation Crosstalk: Implications for Alzheimer's Disease. *Curr Alzheimer Res.* 16, 559-574.

- Pan X., Kaminga A.C., Wen S.W., Wu X., Acheampong K., Liu A. 2015 Dopamine and Dopamine Receptors in Alzheimer's Disease: A Systematic Review and Network Meta-Analysis. *Front Aging Neurosci.* 2019 Jul 11;11:175
- Papp M., Gruca P., Lason-Tyburkiewicz M., Litwa E., Niemczyk M., Tota-Glowczyk K., Willner P. 2017 Dopaminergic mechanisms in memory consolidation and antidepressant reversal of a chronic mild stress-induced cognitive impairment *Psychopharmacology (Berl)*. 234, 2571-2585.
- Papp M., Gruca P., Lason M., Niemczyk M., Willner P. 2019 The role of prefrontal cortex dopamine D2 and D3 receptors in the mechanism of action of venlafaxine and deep brain stimulation in animal models of treatment-responsive and treatment-resistant depression. *J Psychopharmacol.* 33, 748-756
- Park J.E., Kim B.S., Kim K.W., Hahm B.J., Sohn J.H., Suk H.W., Lee J.Y., Cho M.J.. 2019 Decline in the Incidence of All-Cause and Alzheimer's Disease Dementia: a 12-Year-Later Rural Cohort Study in Korea. *J Korean Med Sci.* 8;34(44):e293.
- Parker C. A., Gunn R. N., Rabiner E. A., Slifstein M., Comley R., Salinas C., Johnson C. N., Jakobsen S., Houle S., Laruelle M., Cunningham V. J., Martarello L. 2012 Human Kinetic Modeling of the 5HT6 PET Radioligand 11C-GSK215083 and Its Utility for Determining Occupancy at Both 5HT6 and 5HT2A Receptors by SB742457 as a Potential Therapeutic Mechanism of Action in Alzheimer Disease. *J Nucl Med.* 53, 295-303.
- Parker C.A., Rabiner E.A., Gunn R.N., Searle G., Martarello L., Comley R.A., Davy M., Wilson A.A., Houle S., Mizrahi R., Laruelle M., Cunningham V.J. 2015 Human Kinetic Modeling of the 5HT6 PET Radioligand 11C-GSK215083 and Its Utility for Determining Occupancy at Both 5HT6 and 5HT2A Receptors by SB742457 as a Potential Therapeutic Mechanism of Action in Alzheimer Disease. *J Nucl Med.* 56, 1901-1909.
- Parras-Damas, A, Saura, CA 2019 Synapse-to-nucleus signaling in neurodegenerative and neuropsychiatric Disorders. *Biol Psy* 86, 87-96.
- Parsons C. G., Danysz W., Dekundy A., Pulte I. 2013 Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's disease. *Neurotox Res.* 24, 358-369.
- Parsons C.G., Danysz W., Quack G. 1999 Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data. *Neuropharmacology.* 38, 735-767.
- Peralta V., Cuesta M.J. 2017 Motor Abnormalities: From Neurodevelopmental to Neurodegenerative Through "Functional" (Neuro)Psychiatric Disorders. *Schizophr Bull.* 43, 956-971.
- Piau, A, Wild, K; Mattek, N, Kaye, J 2018 Current state of Digital Biomarker Technologies for real-life, home-based monitoring of cognitive function for Mild Cognitive Impairment to mild Alzheimer

Disease and implications for clinical care; a systematic Review. *J Med Internet Res* 2019 Aug 30;21(8):e1278.

Porcelli S., Van Der Wee N., van der Werff S., Aghajani M., Glennon J.C., van Heukelum S., Mogavero F., Lobo A., Olivera F.J., Lobo E., Posadas M., Dukart J., Kozak R., Arce E., Ikram A., Vorstman J., Bilderbeck A., Saris I., Kas M.J. Serretti A. 2019 Social brain, social dysfunction and social withdrawal. *Neurosci Biobehav Rev.* 97, 10-33.

Prickaerts J., Heckman P.R.A., Blokland A. 2017 Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer's disease. *Expert Opin Investig Drugs.* 26,1033-1048

Radhakrishnan R., Nabulsi N., Gaiser E., Gallezot J. D., Henry S., Planeta B., Lin S. F., Ropchan J., Williams W., Morris E., D'Souza D. C., Huang Y., Carson R. E., Matuskey D. 2018 Age-Related Change in 5-HT₆ Receptor Availability in Healthy Male Volunteers Measured with ¹¹C-GSK215083 PET. *J Nuclear Med* 59, 1445-1450

Ramirez, M. J., 2013. 5-HT₆ receptors and Alzheimer's disease. *Alzheimers Res Ther* 5, 15.

Ravona-Springer R., Davidson M. 2014 Considerations in psychotropic treatments in dementia--can polypharmacy be avoided? *Int J Neuropsychopharmacol.* 17, 1107-1117

Rochais C., Lecoutey C., Gaven F., Giannoni P., Hamidouche K., Hedou D., Dubost E., Genest D., Yahiaoui S., Freret T., Bouet V., Dauphin F., Sopkova de Oliveira Santos J., Ballandonne C., Corvaisier S., Malzert-Fréon A. Novel multitarget-directed ligands (MTDLs) with acetylcholinesterase (AChE) inhibitory and serotonergic subtype 4 receptor (5-HT₄R) agonist activities as potential agents against Alzheimer's disease: the design of donecopride. *J Med Chem.* 58, 3172-3187.

Rupniak, MJ, Kramer, MS 2017 NK1 receptor antagonists for depression: Why a validated concept was abandoned. *J Affect Disorder* 223, 121-125.

Rychtyk, J., Partyka, A., Gdula-Argasinska, J., Myslowska, K., Wilczynska, N., Jastrzebska-Wiesek, M., Wesolowska, A., 2019. 5-HT₆ receptor agonist and antagonist improve memory impairments and hippocampal BDNF signaling alterations induced by MK-801. *Brain Res.* 1722, 146375.

Ryu J.C., Zimmer E.R., Rosa-Neto P., Yoon S.O. 2019 Consequences of Metabolic Disruption in Alzheimer's Disease Pathology. *Neurotherapeutics.* 16, 600-610.

Saavedra, O.M., Karila, D., Brossard, D., Rojas, A., Dupuis, D., Gohier, A., Mannoury la Cour, C., Millan, M.J., Ortuno, J.C., Hanessian, S., 2017. Design and synthesis of novel N-sulfonyl-2-indoles that behave as 5-HT₆ receptor ligands with significant selectivity for D₃ over D₂ receptors. *Bioorg. Med. Chem.* 25, 38–52.

Sabbagh M.N., Hendrix S., Harrison J.E. 2019 FDA position statement "Early Alzheimer's disease: Developing drugs for treatment, Guidance for Industry". *Alzheimers Dement* 10, 13-19.

Sahoo A.K., Dandapat J., Dash U.C., Kanhar S. 2018 Features and outcomes of drugs for combination therapy as multi-targets strategy to combat Alzheimer's disease. *J Ethnopharmacol. Apr* 6;215:42-73.

Saito S., Yamamoto Y., Ihara M. 2019 Development of a Multicomponent Intervention to Prevent Alzheimer's Disease. *Front Neurol.* 2019 May 8;10:490.

Sala Frigerio C., De Strooper B. 2016 Alzheimer's Disease Mechanisms and Emerging Roads to Novel Therapeutics. *Annu Rev Neurosci.* 39, 57-79

Saavedra O.M., Karila D., Brossard D., Rojas A., Dupuis D., Gohier A., Mannoury la Cour C., Millan M.J., Ortuno J.C., Hanessian S. 2017 Design and synthesis of novel N-sulfonyl-2-indoles that behave as 5-HT₆ receptor ligands with significant selectivity for D₃ over D₂ receptors. *Bioorg Med Chem.* 25, 38-52.

Scheltens P., Blennow K., Breteler M.M., de Strooper B., Frisoni G.B., Salloway S., Van der Flier W.M. 2016 Alzheimer's disease. *Lancet* 388, 505-517.

Schmidt R., Hofer E., Bouwman F.H., Buerger K., Cordonnier C., Fladby T., Galimberti D., Georges J., Heneka M.T., Hort J., Laczó J., Molinuevo J.L., O'Brien J.T., Religa D., Scheltens P., Schott J.M., Sorbi S. 2015 EFNS-ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer's disease. *Eur J Neurol.* 22, 889-898.

Sevigny J., Chiao P., Bussière T., Weinreb P.H., Williams L., Maier M.V., Dunstan R., Salloway S., Chen T., Ling Y., O'Gorman J., Qian F., Arastu M., Li M, Chollate S, Brennan M.S., Quintero-Monzon O, Scannevin R.H., Arnold H.M., Engber T., Rhodes K., Ferrero J, Hang Y, Mikulskis A., Grimm J., Hock C., Nitsch R.M., Sandrock A. 2016 The antibody aducanumab reduces A β plaques in Alzheimer's disease. *Nature.* 537, 50-56

Sokoloff P., Le Foll B. 2017 The dopamine D₃ receptor, a quarter century later. *Eur J Neurosci.* 45, 2-19

Sokoloff P., Leriche L., Diaz J., Louvel J., Pumain R. 2013 Direct and indirect interactions of the dopamine D₃ receptor with glutamate pathways: implications for the treatment of schizophrenia. *Naunyn Schmiedebergs Arch Pharmacol.* 386, 107-124.

Staroń J., Kurczab R., Warszycki D., Satała G., Krawczyk M., Bugno R., Lenda T., Popik P., Hogendorf A.S., Hogendorf A., Dubiel K., Matłoka M., Moszczyński-Pętkowski R., Pieczykolan J., Wiczorek M., Zajdel P., Bojarski A.J. 2019 Virtual screening-driven discovery of dual 5-HT₆/5-HT_{2A} receptor ligands with pro-cognitive properties. *Eur J Med Chem.* 2019 Nov 7:11185.

- Sun J.L., Stokoe S.A., Roberts J.P., Sathler M.F., Nip K.A., Shou J., Ko K., Tsunoda S., Kim S. 2019 Co-activation of selective nicotinic acetylcholine receptors is required to reverse beta amyloid-induced Ca^{2+} hyperexcitation. *Neurobiol Aging*. 84, 166-177.
- Swant J., Stramiello M., Wagner J.J. 2008 Postsynaptic dopamine D3 receptor modulation of evoked IPSCs via GABA(A) receptor endocytosis in rat hippocampus. *Hippocampus*. 18, 492-502.
- Takeuchi S., Hida H., Uchida M., Naruse R., Yoshimi A., Kitagaki S., Ozaki N., Noda Y. 2019 Blonanserin ameliorates social deficit through dopamine-D₃ receptor antagonism in mice administered phencyclidine as an animal model of schizophrenia. *Neurochem Int*. 128, 127-134
- Tateno A., Sakayori T., Kim W.C., Honjo K., Nakayama H., Arakawa R., Okubo Y. 2018 Comparison of Dopamine D3 and D2 Receptor Occupancies by a Single Dose of Blonanserin in Healthy Subjects: A Positron Emission Tomography Study With [11C]-(+)-PHNO. *Int J Neuropsychopharmacol*. 21, 522-527
- Teng, L.L., Lu, G.L., Chiou, L.C., Lin, W.S., Cheng, Y.Y., Hsueh, T.E., Huang, Y.C., Hwang, N.H., Yeh, J.W., Liao, R.M., Fan, S.Z., Yen, J.H., Fu, T.F., Tsai, T.F., Wu, M.S., Wang, P.Y., 2019. Serotonin receptor HTR6-mediated mTORC1 signaling regulates dietary restriction-induced memory enhancement. *PLoS Biol*. 17, e2007097.
- Tricco A.C., Ashoor H.M., Soobiah C., Rios P., Veroniki A.A., Hamid J.S., Ivory J.D., Khan P.A, Yazdi F., Ghassemi M., Blondal E., Ho J.M., Ng C.H., Hemmelgarn B, Majumdar SR, Perrier L, Straus SE. 2018 Comparative Effectiveness and Safety of Cognitive Enhancers for Treating Alzheimer's Disease: Systematic Review and Network Metaanalysis. *J Am Geriatr Soc*. 66, 170-178.
- Van den Brink A.C., Brouwer-Brolsma E.M., Berendsen A.A.M., van de Rest O. 2019 The Mediterranean, Dietary Approaches to Stop Hypertension (DASH), and Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) Diets Are Associated with Less Cognitive Decline and a Lower Risk of Alzheimer's Disease-A Review. *Adv Nutr*. 10, 1040-1065.
- Van der Schyf C.J, Geldenhuys WJ, Youdim MB. 2006. Multifunctional drugs with different CNS targets for neuropsychiatric disorders. *J Neurochem*. 99, 1033-1048.
- Van Erum J., Van Dam D., De Deyn P.P. 2019 Alzheimer's disease: Neurotransmitters of the sleep-wake cycle. *Nurosci Biobehav Rev*. 105, 72-80.
- Veitch D.P., Weiner M.W., Aisen P.S., Beckett L.A., Cairns N.J., Green R.C., Harvey D., Jack C.R. Jr, Jagust W., Morris J.C., Petersen R.C., Saykin A.J., Shaw L.M., Toga A.W., Trojanowski J.Q. 2019 Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative. *Alzheimer's Disease Neuroimaging Initiative*. *Alzheimers Dement*. 15, 106-152.

Verma S., Kumar A., Tripathi T., Kumar A. 2018 Muscarinic and nicotinic acetylcholine receptor agonists: current scenario in Alzheimer's disease therapy. *J Pharm Pharmacol.*70, 985-993.

Visanji N.P., Fox S.H., Johnston T., Reyes G., Millan M.J., Brotchie J.M. 2009 Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease. *Neurobiol Dis.* 35, 184-192.

Umar T., Hoda N. Alzheimer's Disease: A Systemic Review of Substantial Therapeutic Targets and the Leading Multi-functional Molecules. 2017 *Curr Top Med Chem.* 217, 3370-3389.

Wagner, MJ, Luo, L 2020 Neocortex-Cerebellum circuits for cognitive processing; *Trends Neurosci* 43, 42-54.

Wang, L., Lv, Y., Deng, W., Peng, X., Xiao, Z., Xi, Z., Chen, G., Wang, X., 2015. 5-HT6 receptor recruitment of mTOR modulates seizure activity in epilepsy. *Mol. Neurobiol.* 51, 1292–1299.

Watson D.J., Loiseau F., Ingallinesi M., Millan M.J., Marsden C.A., Fone K.C. 2012 Selective blockade of dopamine D3 receptors enhances while D2 receptor antagonism impairs social novelty discrimination and novel object recognition in rats: a key role for the prefrontal cortex. *Neuropsychopharmacology.* 37, 770-786.

Watson D.J., Marsden C.A., Millan M.J., Fone K.C. 2011. Blockade of dopamine D3 but not D2 receptors reverses the novel object discrimination impairment produced by post-weaning social isolation: implications for schizophrenia and its treatment. *Int J Neuropsychopharmacol.*15, 471-484.

Wesołowska A. 2010 Potential role of the 5-HT6 receptor in depression and anxiety: an overview of preclinical data. *Pharmacol Rep.* 62, 564-577.

Wicke, K., Haupt, A., Beshpalov, A., 2015. Investigational drugs targeting 5-HT6 receptors for the treatment of Alzheimer's disease. *Expert Opin Investig Drugs* 24, 1515-1528.

Więckowska A., Wichur T. Godyń J., Bucki A., Marcinkowska M., Siwek A., Więckowski K., Zaręba P., Knez D., Głuch-Lutwin M., Kazek G., Latacz G., Mika K., Kołaczkowski M., Korabecny J., Soukup O., Benkova M., Kieć-Kononowicz K., Gobec S., Malawska B. 2018 Novel Multitarget-Directed Ligands Aiming at Symptoms and Causes of Alzheimer's Disease. *ACS Chem Neurosci.* 16, 195-214.

Wilkinson, D., Windfeld, K., Colding-Jorgensen, E., 2014. Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial. *Lancet Neurol.* 13, 1092–1099.

Wilkinson ST, Sanacora G. 2019 A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems *Drug Discov Today*. 2019 24,606-615.

Wise EA, Rosenberg PB, Lyketsos CG, Leoutsakos JM. 2019 Time course of neuropsychiatric symptoms and cognitive diagnosis in National Alzheimer's Coordinating Centers volunteers. *Alzheimers Dement (Amst)*. 11, 333-339.

Woods, S., Clarke, N. N., Layfield, R., Fone, K. C., 2012. 5-HT(6) receptor agonists and antagonists enhance learning and memory in a conditioned emotion response paradigm by modulation of cholinergic and glutamatergic mechanisms. *Br J Pharmacol* 167, 436-449.

Woolley, M. L., Bentley, J. C., Sleight, A. J., Marsden, C. A., Fone, K. C. F., 2001. A role for 5-HT(6) receptors in retention of spatial learning in the Morris water maze. *Neuropharmacology* 41, 210-219.

Xing B, Meng X, Wei S, Li S. 2010. Influence of dopamine D3 receptor knockout on age-related decline of spatial memory. *Neurosci Lett*. 481, 149-153.

Yahiaoui, S., Hamidouche, K., Ballandonne, C., Davis, A., de Oliveira Santos, J.S., Freret T., Boulouard, M., Rochais, C., Dallemagne, P., 2016. Design, synthesis, and pharmacological evaluation of multitarget-directed ligands with both serotonergic subtype 4 receptor (5-HT4R) partial agonist and 5-HT6R antagonist activities, as potential treatment of Alzheimer's disease. *Eur. J. Med. Chem.* 121, 283–293.

Yun, H.M., Baik, J.H., Kang, I., Jin, C., Rhim, H., 2010. Physical interaction of Jab1 with human serotonin 6 G-protein-coupled receptor and their possible roles in cell survival. *J. Biol. Chem.* 285, 10016–10029.

Yun, H.M., Kim, S., Kim, H.J., Kostenis, E., Kim, J.I., Seong, J.Y., Baik, J.H., Rhim, H., 2007. The novel cellular mechanism of human 5-HT6 receptor through an interaction with Fyn. *J. Biol. Chem.* 282, 5496–5505.

Zhang P., Xu S., Zhu Z., Xu J. 2019 Multi-target design strategies for the improved treatment of Alzheimer's disease. *Eur J Med Chem.* 176, 228-247.

Zott B, Busche MA, Sperling RA, Konnerth A. 2018 What happens with the circuit in Alzheimer's disease *Annu Rev Neurosci.* 2018 Jul 8;41:277-29.

Figure 1

Auguste D., the first case of AD

Cardinal Symptoms:


Cognitive deficits

Disorganised language

Confusion

**Perturbed sleep
and circadian rhythms**

**Psychiatric symptoms
(depression, anxiety,
psychosis, aggression..)**



Risk Factors:

Old age

Toxins, Heavy metals, Pollution

Infections, Chronic Stress


**ApoE4 genotype, Down
Syndrome, Depression**

High fat diet, Obesity, Diabetes

**Hypertension, Stroke, Epilepsy
TBI, Encephalopathies**

Highly heterogeneous, mainly idiopathic disorder

MAJOR DEPRESSION



ALZHEIMER'S DISEASE




Figure 2

Figure 3






Figure 4




Rapamycin, selective mTOR inhibitor; WAY181,187, selective 5-HT₆ agonist and SB258,585, selective 5-HT₆ antagonist

Figure 5

Dizolcipine: blockade of disruption of social recognition



D-Serine: facilitation of promotion of social recognition



Dizolcipine, selective NMDA antagonist; D-Serine, selective GlycineB/NMDA agonist and SB271,046, selective 5-HT₆ antagonist

Figure 6






Figure 7



S33084, selective D_3 antagonist and **SB271,046**, selective $5-HT_6$ antagonist


Figure 8

Facilitation of social recognition




S33084, selective D₃ antagonist, and SB271,046 and SB258,585, selective 5-HT₆ antagonists


Figure 9




SB737,050:
5-HT₆, 9.0; D₃, 7.9; D₂, 7.7



PZ-1643:
5-HT₆, 7.6; D₃, 8.2; D₂, 6.5




Compound 13b:
5-HT₆, 6.8; D₃, 6.6; D₂, 5.2




Compound 45 (enantiomer 1):
5-HT₆, 8.7; D₃, 9.0; D₂, 7.4

Figure 10


h5-HT₆ blockade (Aden. Cyclase)




hD₃ blockade (Gi/o)



hD_{2L} blockade (Gi/o)



↓ DEFICIT SOCIAL RECOGNITION



ANXIOLYTIC ACTIONS





Figure 11

Novel object
recognition test



Social
recognition test





Figure 12

Association of dual pharmacological activities to reinforce therapeutic efficacy in the treatment of AD



DUAL-ACTING AGENTS FOR IMPROVING COGNITION AND REAL-WORLD FUNCTION IN ALZHEIMER'S DISEASE: FOCUS ON 5-HT6 AND D3 RECEPTORS AS HUBS

Mark J. Millan*, Anne Dekeyne*, Alain Gobert*, Mauricette Brocco, Clotilde Mannoury la Cour*, Jean-Claude Ortuno, David Watson*** and Kevin C.F. Fone*****

HIGHLIGHTS

We need better drugs for cognitive and psychiatric symptoms of Alzheimer's disease.

Selective antagonists at 5-HT6 receptors failed in late-phase clinical trials.

Multi-target 5-HT6 agents with complementary actions may be more effective.

D3 antagonists express broad-based, pro-cognitive actions in rodents.

Dual-acting 5-HT6/D3 antagonists should improve cognition in Alzheimer's disease.